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G-Quadruplex DNA (QDNA) motifs have been observed to form in various important 
regions of the human genome, contributing to cellular processes such as gene 
expression, DNA replication, and telomere maintenance. The relevance of these 
processes to cancer cell function and proliferation has drawn recent attention towards 
QDNA as a therapeutic target. This project contributes to the field by synthesising 
several heteroleptic platinum(II) complexes for the purpose of stabilising QDNA. 
A total of twelve novel heteroleptic complexes were synthesised, based on previously 
reported homoleptic bis-phenanthroline complexes. Of the synthesised complexes, 
ten incorporated the 4,7-diphenyl-1,10-phenanthroline ligand in combination with 
either a polyaromatic ligand (PL) or a diamminocyclohexane (DACH) enantiomer. The 
remaining two complexes incorporated 1,10-phenanthroline in combination with 
another PL. Interestingly, these bis-phenanthroline complexes were found to be quite 
labile, thus various methods of microwave-assisted synthesis were investigated.  
The QDNA binding affinity of the complexes was assessed using a combination of 
docking simulations, electrospray ionisation mass spectrometry (ESI-MS) binding 
experiments, and circular dichroism (CD) experiments. All the of the tested complexes 
exhibited a good binding affinity for QDNA, with a direct correlation observed between 
complex aromaticity and binding affinity.   
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UV Ultra violet 
UV-Vis Ultraviolet-visible 
ε Extinction coefficient  
λmax Maximum peak 












1. Introduction  
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1.1. Cancer  
The term cancer describes a vast range of diseases which result from abnormal cell 
growth.1 In most instances, cancer is a result of genetic mutations caused by 
environmental factors, however, a small number of cases are hereditary. Cancer has 
a significant global burden, with 9.5 million cancer deaths and 17 million new cancer 
diagnoses reported in 2018.2 In Australia, 1 in 2 individuals are diagnosed with some 
form of cancer by the age of 85, with breast, prostate, colorectal, skin melanoma and 
lung cancer accounting for 60% of all diagnoses (Figure 1.1).3 
Figure 1.1 Incidence and mortality rates of the ten most common cancers in Australia.3 
1.2. A brief history of chemotherapy 
The use of chemotherapeutics to treat cancer originates from the development of 
chemical warfare agents, most notably mustard gas (Figure 1.2), during World War I. 



























concerns over their use during World War II prompted an investigation into their side-
effects, bringing to light their myelosuppressive effect. This led to the discovery of the 
anticancer potential of nitrogen mustards by Yale pharmacologists Alfred Gilman and 
Louis S. Goodman.4 As mustard gas was too volatile to be used in a clinical setting, 
Gilman and Goodman developed the more stable compound chlormethine (Figure 
1.2). Also known as mustine, this compound was initially trialled for the treatment of 
patients with malignant lymphoma in 1942. Whilst remission was observed in several 
cases, severe toxicity towards healthy cells in clinical usage resulted in its 
discontinuation. Subsequently, several other nitrogen mustard derivatives were 
developed, most notably chlorambucil,5 which currently remains as a treatment for 
chronic lymphocytic leukaemia. Such compounds were termed alkylating agents, due 
to their ability to readily alkylate biological targets such as DNA, RNA and proteins 
(Figure 1.2).6  
Figure 1.2 Chemical structure of mustard gas and its derivatives Chlormethine and 
Chlorambucil. 




Due to the limitations of chlormethine and its derivatives, such as nephrotoxicity and 
immunosupression, research began on alternative approaches to chemotherapy.7 
One such approach was the development of folic acid antagonists, based on the 
observation that folate deficiency results in compromised bone marrow function. This 
led to the development of a number of folic acid antagonists by Sidney Farber in the 
1940s. Of these, the compound methotrexate (Figure 1.3) was found to be the most 
potent, causing remission in acute childhood leukaemia.8 Despite significant toxicity 
towards healthy cells, it is still used for the treatment of leukaemia and several other 
cancers including breast, lung and lymphoma. 
Figure 1.3 Chemical structure of Methotrexate. 
Despite the development of a vast range of chemotherapeutics by the mid-1960s, 
effective treatments for a broader range of solid tumours were yet be found. This 
eventually changed following the serendipitous discovery of the effects of the 
compound cisplatin — cis-[Pt(NH3)2Cl2] on bacterial cell division by Barnett Rosenberg 
in 1965 (Figure 1.4).9 Subsequent investigation found cis-[Pt(NH3)2Cl2] also exhibited 
potent antitumor activity, eventually leading to its approval by the U.S Food and Drug 
Administration for the treatment of testicular and ovarian cancers in 1978.10  
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Figure 1.4 Contrast of normal E. coli bacterial cells (left), and bacterial cells grown in the 
presence of cis-[Pt(NH3)2Cl2] (right). Cell division is inhibited, leading to long filamentous 
growth.9 
Cisplatin proved to be revolutionary at the time, increasing the survival rate of testicular 
cancer drastically from 10% to 90%, making cisplatin the only chemotherapeutic to 
have effectively ‘cured’ any type of cancer.11 Cisplatin has since seen widespread use 
in the treatment of several solid malignancies, including testicular, ovarian, lung, 
esophageal and head and neck cancers.12 Like other chemotherapy treatments, the 
use of cisplatin is not without limitations, most notably dose-limiting toxicities in 
addition to cancer cell drug resistance.  
Given the limitations of cisplatin, researchers were quick to begin the investigation of 
analogous compounds in an attempt to reduce toxicity towards healthy cells. Despite 
a substantial global research effort, only two cisplatin analogues have since reached 
worldwide approval. The first of which was carboplatin, approved in 1986 as a cisplatin 
alternative. Relative to cisplatin, carboplatin was found to have reduced side effects 
at the expense of reduced activity.13 Oxaliplatin was approved next in 1996 for the 
treatment of colorectal cancer and when used in combination with other drugs, such 
as 5-fluorouracil, was found to significantly reduce the chances of patient relapse.13-
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15. Several other platinum chemotherapeutics have since been approved for use in 
specific countries. These include heptaplatin, lobaplatin, and nedaplatin (Figure 1.5). 
These drugs are approved for clinical use in South Korea, China and Japan, 
respectively.10, 16 Overall, platinum based chemotherapeutics play an important role in 
chemotherapy, accounting for an estimated 50% of all treatments worldwide.17, 18  
Figure 1.5 Chemical structures of current approved platinum drugs. 
1.3. Mechanisms of action for current Platinum drugs 
The mechanism of cisplatin is generally accepted to be the formation of platinum-DNA 
adducts.15 To form these adducts, one of the chloride atoms must first be displaced to 
form the mono-aquated complex cis-[PtCl(NH3)2(H2O)]+.19 In the blood, the chloride 
concentration is approximately 100 mM, thus this displacement is inhibited from 
occurring. However, once the complex enters the cell via passive diffusion or other 
means, the intracellular chloride concentration is substantially lower (~4-5 mM). This 
results in the dissociation of one of the chloride atoms by a water molecule, occurring 
either once or twice to produce the mono or bis-aquated species, respectively.19 The 
coordinated water molecule may then be displaced by one of the nitrogen atoms 
Cisplatin Carboplatin Oxaliplatin 
Neplatin Heptaplatin Lobaplatin 
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present on DNA, typically the N7 of guanine. The resultant cis-[PtCl(NH3)2(DNA)]+ or 
cis-[Pt(H2O)(NH3)2(DNA)]+complex may then covalently bind to another guanine, 
forming either inter- or intra-strand crosslinks between two DNA strands.15 A summary 
of this mechanism is depicted in Figure 1.6. 
Figure 1.6 Cisplatin mechanism of action. Cell image sourced under a creative commons 
license.20 Cisplatin-DNA adduct sourced from protein data bank, PDB: IAIO and generated in 
UCSF Chimera. 
Carboplatin is believed to operate predominantly under the same mechanism as 
cisplatin, with the bidentate dicarboxylate ligand serving as a leaving group for 
displacement.13 Oxaliplatin is believed to function via several mechanisms due to its 
synergistic effects with other platinum drugs.14 However, the primary mechanism is 
similarly believed to be formation of platinum-DNA adducts, where the oxalate 
functional group acts as a leaving group analogous to cisplatin and carboplatin.14   
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1.4. Major limitations of platinum drugs 
The mechanisms of platinum drugs are non-specific, and thus they accumulate in 
rapidly dividing healthy cells in addition to cancerous cells. This results in various side-
effects including nephrotoxicity, myelosuppression, immunosuppression, nausea, 
vomiting and peripheral neuropathy.13, 15, 21 These side-effects are typically quite 
severe in nature, and can vary greatly from patient to patient. Due to the severity and 
long-term issues that can be caused by these side effects, patients may be forced to 
reduce treatment dosage or frequency, or in acute cases, cease treatment; both 
outcomes leading to poorer patient prognosis.22  
Tumour-drug resistance is another major problem encountered by current 
chemotherapy treatments. There are two main two types of tumour-drug resistance; 
intrinsic and acquired.23 Intrinsic resistance arises prior to treatment, and is defined as 
an absence of tumour response to treatment. For example, cisplatin shows limited 
activity in colorectal, lung and prostate cancers.24 Acquired resistance differs however, 
in that it occurs as a response to treatment. This is particularly problematic in cases 
of prolonged treatment; as resistance can often develop prior to tumour remission. 
Increased DNA repair is believed to be one of the most common forms of acquired 
resistance;25 the most prevalent form of which is the activation of nucleotide excision 
repair pathways.26 This pathway functions via removal of the segment of single 
stranded DNA containing the platinum-DNA adduct. The remaining strand of DNA is 
then repaired by the addition of complementary base pairs. Several other DNA repair 
pathways have been proposed to contribute to acquired resistance, including 
homologous recombination and DNA mismatch repair, but their frequency varies 
between cell lines.21, 25  
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Several drug specific resistance mechanisms have also been observed. For cisplatin, 
these include reduced cellular drug uptake, increased drug efflux, or increased 
inactivation of the drug through binding to thiol groups present in molecules such as 
glutathione.24, 27 For both cisplatin and carboplatin, platinum-drug mediated 
degradation of Copper transporter 1 (CTR1) is believed to contribute to reduced 
cellular uptake.28 Both drugs are believed to use this transporter protein as a means 
to enter the cell. Whilst the exact mechanism is currently under debate, it is believed 
that the influx of these drugs elicits a cellular response similar to copper overload; this 
leads to reduced expression of CTR1 and consequently reduced drug intake.28-30 
Oxaliplatin resistance is not as well-understood, as the mechanism attributed to its 
differing cytotoxicity to both cisplatin and carboplatin has not yet been accounted for. 
Several tentative mechanisms for resistance involving ABC transporters, solute carrier 
transporters, and Glutathione S-transferases have been suggested.31, 32  
1.5. Canonical forms of DNA 
Currently approved platinum chemotherapy drugs have been reported to form adducts 
predominantly with duplex DNA. Duplex DNA, or double stranded DNA (dsDNA), is 
formed through hydrogen bonding interactions between the nucleobases of two 
complementary DNA strands.33 In dsDNA, a guanine (G) base will always pair with 
cytosine (C), and an adenine (A) base will always pair with thymine (T) (Figure 1.7). 
The specific ordering of these base pairs determines what is known as the tertiary, or 
higher order structure, of the DNA. 
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Figure 1.7 Watson-Crick base pairings observed in dsDNA. 
There are three main biologically relevant higher order structures of duplex DNA: A-
DNA, B-DNA and Z-DNA (Figure 1.8). Of these structures, B-DNA is the most common 
form found in vivo. B-DNA is a right-handed double helical form of DNA which makes 
one turn approximately every 10 base pairs, resulting in a wide major groove, and a 
narrower minor groove.34 Due to this key structural difference, most proteins and small 
drug molecules will bind preferentially to the major groove.35 A-DNA, whilst less 
common, is observed to form under dehydrating conditions. Relative to B-DNA, A-
DNA incorporates more base pairs per turn (~12), resulting in a more tightly wound 
helix.36 This gives rise to a deeper, narrower major grove compared to B-DNA, in 
addition to a shallower minor groove. As a result, most proteins that bind to B-DNA 
will not bind to A-DNA. Z-DNA however, differs from both A and B-DNA, being a left-
handed helical structure.37 This conformational difference arises due to an alternating 
syn and anti-conformation of stacked base pairs. Under standard physiological 
conditions, formation of this structure is unfavourable, however it has been observed 
to form in instances of high salt concentrations, negative supercoiling, or in the 
presence of long alternating G-C to C-G sequences.38 Whilst the exact function of this 
type of DNA is still under speculation, Z-DNA is believed to play an important role in 
transcription.39   
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Figure 1.8 Canonical forms of duplex DNA. Protein Data Bank codes (PDBs) are specified 
below each motif. Images generated using UCSF Chimera. 
1.6. Non-canonical forms of DNA 
Whilst dsDNA is the predominant form of DNA, various non-canonical forms of DNA 
have also been reported (Figure 1.9). Some notable examples include: triplexes 
(Watson-Crick pairing between B-DNA and an additional strand of DNA to form a triple 
helix), hairpin loops (self-association of single-stranded DNA to form a stem-loop 
structure), cruciforms (a cross shaped ds-DNA structure), G-quadruplexes (G-rich 
DNA motifs formed by non-canonical G base pairing) and intercalated-motifs (C-rich 
DNA motifs formed by non-canonical C base pairing).40-44 Both G-quadruplexes and 
Intercalated-motifs are of specific interest as potential chemotherapeutic targets, 










Figure 1.9 Various non-canonical DNA motifs. Images generated using UCSF Chimera. 
1.6.1. G-quadruplexes 
G-quadruplexes (QDNA) are a secondary structure of DNA found in guanine rich 
sequences of DNA or RNA. G-quadruplexes are formed from the stacking of two or 
more consecutive guanine tetrads; a non-canonical association between four guanine 
bases. This non-conventional base pairing occurs via Hoogsteen hydrogen bonding 
and is typically stabilised by cations such as potassium (Figure 1.10).46 Presently, a 
vast library of QDNA topologies have been documented, including parallel, 
antiparallel, and hybrid structures forming from the folding of one, two, or four G-rich 
strands.40, 46, 47 Biologically relevant G-quadruplexes have been identified in several 













promoter regions, G-rich RNA regions, and segments DNA occurring at the end of 
telomeres.48-50  
Figure 1.10 Structure of Hoogsteen H-bonding association between four guanine bases to 
form a guanine tetrad. 
1.6.2. Intercalated motifs 
Intercalated-motifs (i-motifs) are a more recently discovered cytosine rich form of 
DNA.43 Like QNDA, i-motifs are a type of quadruplex structure, instead forming from 
cytosine rich strands of DNA. This structure is formed by Hoogsteen hydrogen bonding 
interactions between two cytosine base pairs, typically abbreviated C.C+ (Figure 
1.11).51 These structures have been observed to be most stable when the nitrogens 
involved in the C.C+ bonding are hemiprotonated, i.e protonated at half of all sites. 
This phenomenon occurs around pH 5–6; however, there is evidence that i-motifs may 
also form at a physiological pH.52-54 Presently, the biological significance of i-motifs is 
still under investigation, however they have been observed to form in human telomeric 




Figure 1.11 C.C+ base pairing. Protonated cytosine nucleobase highlighted in red. 
1.7. G-quadruplexes as an anticancer target 
To overcome the limitations of current chemotherapy treatments, recent research has 
seen the investigation of non-canonical motifs of DNA as new potential drug targets. 
Relative to other non-canonical forms of DNA, G-quadruplexes have seen rigorous 
investigation. Several biologically relevant quadruplexes have been observed to form 
in various regions of telomeric DNA, and the regulatory regions of oncogenes; both of 
which play an important role in cancer cell proliferation.  
The formation of G-quadruplexes in telomeric DNA is of specific interest due to the 
role of telomeric DNA in cancer. Each time a sequence of DNA is replicated, a small 
segment of telomeric DNA is lost. In a healthy cell, this process will repeat until the 
telomere reaches a ‘critical length’, from which the telomere loses function, thus 
signalling cell death through apoptosis.56 In 90% of tumours, this process is avoided 
due to the upregulation of the enzyme telomerase which adds a 5 '-TTAGGG repeat 
to the end of the telomere.56, 57 Recent research has demonstrated that the single-
stranded 3’-overhang at the end of a telomere can fold into a G-quadruplex in vivo.40 
More importantly, the formation of these quadruplexes has been shown to 
considerably reduce the activity of the enzyme telomerase.58 Consequently, a new 
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target for drug design has emerged, based upon the design molecules to stabilise 
QDNA.40, 47, 59, 60  
1.8. Designing a QDNA stabiliser 
Presently, a wide range of compounds have been investigated for G-quadruplex 
binding affinity, although a vast majority include organic ligands. Of these, quarfloxin 
is the only G-quadruplex stabilising molecule that has reached clinical trials (Figure 
1.12).60 Interestingly, whilst most QDNA stabilising compounds have been observed 
to be selective for telomeric DNA, quarfloxin was found to be selective for ribosomal 
DNA, resulting in the inhibition of ribosomal RNA synthesis.61 This compound had 
passed phase II trials for the treatment of B-Cell chronic lymphocytic leukaemia, 
however, it was later withdrawn due to its low bioavailability and excessive binding to 
albumin. Several other notable molecules have also demonstrated strong G-
quadruplex binding affinity, most notably 2,6-diamidoanthraquinone derivatives, and 
telomestatin; a potent telomerase inhibitor isolated from the bacteria Streptomyces 
anulatus (Figure 1.13).62 
Figure 1.12 Chemical structure of quarfloxin. 
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Figure 1.13 Chemical structure of telomestatin. 
Based on the structural properties of these compounds and others, several ideal 
structural properties for new compounds have been proposed. Great importance is 
placed on maximising π-π stacking and electrostatic interactions, so that a potential 
drug will bind non-covalently to the external surface of a quadruplex.59, 63, 64 To 
encourage this mode of binding, a large, electron deficient aromatic surface is 
preferred.63 As a result, a higher degree of selectivity for QDNA may be achieved by 
designing larger aromatic surfaces that exceed the surface area of a typical duplex.59 
In addition, a positive charge positioned centrally relative to the G-quartet has been 
observed to have a potent stabilising effect, mimicking the role of Na+ and K+ cations, 
which typically reside within the central cavity.59 Positively charged functional groups 
have also been evidenced to increase binding affinity as they are able to interact with 
the loops and folds of the G-quartet, however this approach has currently seen limited 
investigation.59 
Metallo-organic complexes, in particular Pt(II) complexes, are promising candidates 
as quadruplex stabilisers, as various aromatic ligands can be coordinated to maximise 
π-π stacking and electrostatic interactions, whilst the metal centre provides a 
17 
 
conveniently centralised positive charge. Presently, very few metal complexes have 
been synthesised specifically for the stabilisation of G-quadruplexes. Nonetheless, 
several complexes incorporating terpyridine, salphen, or 1,10-phenanthroline ligand 
derivatives have been shown to be effective quadruplex stabilising molecules.63-66  
1.9. Project aims 
The aims of this project were to synthesise a range of several novel platinum(II) 
complexes incorporating planar aromatic ligands and to determine their binding affinity 
for QDNA. Homoleptic bis-phenanthroline and bipyridine based Pt(II) complexes have 
previously been identified as effective quadruplex stabilisers,63, 67, 68 however, 
analogous heteroleptic complexes are yet to be reported. Previous studies have 
demonstrated that [Pt(4,7-diphenyl-1,10-phenanthroline)2](PF6)2 exhibits a strong 
binding affinity and selectivity toward quadruplex DNA.67, 68 This molecular framework 
inspired the design of several complexes following the general structure [Pt(4,7-
diphenyl-1,10-phenanthroline)(PL)]2+, where PL denotes a planar aromatic ligand such 
as 1,10-phenanthroline or 2,2′-bipyridine (Figure 1.14). 
 Figure 1.14 Example complexes incorporating the 4,7-diphenyl-1,10-phenanthroline motif. 
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Molecular docking simulations between the synthesised complexes and various 
dsDNA or QDNA motifs would provide insights into potential binding mechanisms and 
relative binding affinity. These data would then be compared to ESI-MS binding 
experiments and CD melting studies to produce an overall assessment of binding 
affinity. Moreover, it was expected that a trend may be observed between various 
















Reagents were used as received unless otherwise specified. Solvents used were of 
analytical grade or higher and purchased from Sigma-Aldrich or Chem-Supply. 
Potassium tetrachloroplatinate (K2PtCl4) was purchased from Precious Metals Online. 
The ligands 1,10-phenanthroline (phen), 4,7-diphenyl-1,10-phenanthroline 
(bathophen), 4,7-dimethyl-1,10-phenanthroline (47Me2phen), 5,6-dimethyl-1,10-
phenanthroline (56Me2phen), 3,4,7,8-tetramethyl-1,10-phenanthroline (tmp), 5-
chloro-1,10-phenanthroline (5ClPhen), 2,2′-bipyridine (bpy), 4,4′-dimethyl-2,2′-
bipyridine (44Me2bpy), 5,5′-dimethyl-2,2′-bipyridine (55Me2bpy), (1S,2S)-(+)-
diaminocyclohexane (S,S-DACH) and (1R,2R)-(−)-diaminocyclohexane (R,R-DACH) 
were purchased from Sigma-Aldrich or Alfa Asear. The deuterated solvents deuterium 
oxide (D2O), acetonitrile-d3 (CD3CN), methanol-d4 (MeOD) and dimethylsulphoxide-d6 
(DMSO-d6) were purchased from Cambridge Isotope Laboratories. Biotage SNAP KP-
C18-HS (12 g and 30 g) columns were obtained from Biotage. Sep-pak C18 (20 cc, 5 g) 
cartridges were obtained from Waters. 
2.2. Instrumentation 
2.2.1. NMR Spectroscopy 
NMR experiments were performed on a Bruker Avance 400 MHz NMR spectrometer. 
Samples were made up to 450 μL in 5 mm OD NMR tubes and internally referenced 
to the residual solvent peak. 1H spectra were obtained with a spectral width of 14 ppm 
over 128 accumulations. 1H-195Pt HMQC spectra were obtained with a 12 ppm spectral 
width and 128 data points in the F1 dimension (1H nucleus), and a 2500 ppm spectral 
width with 2048 data points in the F2 dimension (195Pt nucleus). NOESY spectra were 
obtained using a spectral width of 8 ppm with 256 data points in the F1 dimension and 
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2048 data points in the F2 dimension. All spectra were processed with Bruker TopSpin 
3.0 using the following commands: automatic phase correction and automatic base 
line subtraction. 
2.2.2. High resolution mass spectrometry 
High resolution mass spectrometry (HRMS) was performed using a Waters SYNAPT 
G2-S QTOF MS. The instrument was configured to positive ion mode, with a mass 
range of 50 to 1000 Da. A sodium iodide reference and leucine enkephalin lockmass 
was used. Samples were prepared in methanol and diluted to a concentration of ~0.2 
µM. Spectra were processed using Waters MassLynx 4.2 with no post-processing 
applied. 
2.2.3. UV-Visible absoprtion spectroscopy 
UV-Vis spectra were obtained using a Cary 3500 UV-Vis spectrophotometer. All 
experiments were performed at room temperature using a 1 cm quartz cell with a 
wavelength range of 200–400 nm. Each spectrum was baseline corrected and the 
absorbance plotted against the concentration to determine the extinction coefficient 
(ε). This data was obtained by titration of a stock solution of the metal complex into a 
solvent of known volume. Water was used as the solvent for all tested samples.  
2.2.4. High Performance Liquid Chromatography 
Reverse phase analytical HPLC was performed using an Agilent 1260 infinity binary 
series instrument comprised of five modules; a 1260 Binary Pump, 1260 ALS, 1260 
TCC, 1260 HIP Degasser, and 1260 DAD. All analysis was performed using a 
4.6 x 100 mm Phenomenex Onyx Monolithic reverse-phase C18 column. The two 
mobile phases consisted of 0.06% TFA in H2O (eluent A) and 0.06% TFA in 90% 
acetonitrile and 10% H2O (eluent B). All samples were analysed using a 0-50% or 
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0- 100% eluent B gradient over 15 minutes, followed by a 5-minute 100% eluent B 
flush. The column was re-equilibrated between samples using a 100% eluent A wash. 
For all analyses a flow rate of 1.0 mL min−1 was used with peak detection at 214 and 
254 nm. 
2.2.5. Column chromatography 
Column chromatography was performed using either a Biorad peristaltic pump in 
combination with a UV-Vis detection unit or a Biotage Isolera One flash purification 
system. All purification was performed using Biotage SNAP KP-C18-HS (12 or 30 g) 
columns or Sep-pak C18 (20 cc, 5 g) cartridges. Mobile phases consisted of ultrapure 
water, HPLC grade acetonitrile or HPLC grade methanol. 
2.2.6. Synchrotron radiation circular dichroism 
SRCD spectroscopy data for complex 11 and 12 were obtained using the AU-CD 
beamline on ASTRID2 at ISA, Aarhus University, Denmark. ASTRID2 operates in top-
up mode with a current of 120 mA. The AU-CD beamline operates in a wavelength 
range of 125–450 nm, with a bandwidth of 0.6 nm. The beam size on the sample is 2 
(vertical) × 6 mm (horizontal) with a sample to detector distance of 25 mm. Calibration 
of the spectropolarimeter was carried out using d-10-camphorsulfonic acid. Data was 
collected between 375–175 nm with 1 nm increments. Six accumulations were 
obtained at 25 °C using a suprasil quartz cuvette with a path length of 0.01 cm. Both 
samples were prepared in H2O. A H2O baseline was obtained and subtracted from 
each spectrum. 
2.2.7. Microwave reactions 
Microwave reactions were performed using a CEM Discover SP or Biotage Initiator 
microwave reactor. Reactions performed with the CEM Discover SP microwave 
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reactor utilised 10 mL or 35 mL borosilicate glass reaction vessels in conjunction with 
multi-use Teflon lids. Reactions performed with the Biotage initiator microwave reactor 
utilised 20 mL quartz vials equipped with single-use PTFE lids. All reactions were 
performed with H2O as the solvent with a 600 rpm stirring speed and a maximum 
pressure of ~14 Bar at 180 °C. 
2.3. Synthesis 
2.3.1. General synthesis of [Pt(PL)Cl2] starting materials 
Platinum ligand dichlorides were synthesised based on a literature method by 
McFadyen.69 K2PtCl4 was dissolved in a mixed solution of H2O and DMSO (1 mL H2O, 
3 mL DMSO). 1 equivalent of the desired ligand was then solvated in DMSO (10 mL). 
The two solutions then were stirred at 75 °C for 15 minutes or until fully dissolved. The 
solutions were then combined whilst hot and stirred at 75 °C for an additional 30 
minutes. The reaction mixture was then refrigerated at 5 °C for 24 hours, resulting in 
the formation of a yellow precipitate which was collected by vacuum filtration. The 
collected solid was  then washed with H2O, and methanol followed by drying with 
ether. A summary of this process can be seen in Figure 2.1. Individual reagent masses 
and yields are reported in Table 2.1.  
Figure 2.1 General synthesis of [Pt(PL)Cl2] analogues.  
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Table 2.1 Reagents and yields of [Pt(PL)Cl2] starting materials. 
 Starting material  
Compound 
K2PtCl4 Ligand Yield 
mg mmol mg mmol mg mmol % 
[Pt(1,10-phenanthroline)Cl2] 142.0 0.34 63.8 0.35 116.8 0.26 76.5 
[Pt(5-chloro-1,10-phenanthroline)Cl2]a 61.6 0.15 32.3 0.15 41.6 0.09 58.3 
[Pt(3,4,7,8-tetramethyl-1,10-phenanthroline)Cl2] 99.0 0.24 56.4 0.24 95.1 0.19 79.4 
[Pt(4,7-dimethyl-1,10-phenanthroline)Cl2] 71.9 0.17 36.1 0.17 65.1 0.14 79.2 
[Pt(5,6-dimethyl-1,10-phenanthroline)Cl2] 71.9 0.17 36.1 0.17 84.2 0.18 75.2 
[Pt(4,7-diphenyl-1,10-phenanthroline)Cl2] 140.0 0.34 113.3 0.34 155.6 0.26 77.0 
[Pt (2,2′-bipyridine)Cl2] 107.5 0.26 41.3 0.26 88.4 0.21 80.8 
[Pt(4,4′-dimethyl-2,2′-bipyridine)Cl2] 96.5 0.23 43.0 0.23 83.8 0.19 80.1 
[Pt (5,5′-dimethyl-2,2′-bipyridine)Cl2] 98.1 0.24 44.3 0.24 56.0 0.12 52.6 
a [Pt(5-chloro-1,10-phenanthroline)Cl2] formed a fine orange powder 
2.3.2. Synthesis of [Pt(DACH)Cl2] starting materials 
Synthesis of [Pt(DACH)Cl2] starting materials was adapted from a literature method.70 
K2PtCl4 was dissolved in H2O (2 mL). 1 equivalent of the desired enantiomer of 1,2-
diaminocyclohexane was dissolved H2O (3 mL). The two solutions were combined 
then stirred for 15 minutes. The reaction mixture was then refrigerated for 48 hours 
resulting in the formation of a yellow precipitate which was collected by vacuum 
filtration. The collected solid was then washed with H2O, and methanol, followed by 
drying with ether. Individual reagent masses and yields are reported in Table 2.2. 
Table 2.2 Reagents and yields of [Pt(DACH)Cl2] starting materials. 
 Starting materials  
Compound K2PtCl4 Ligand Yield 
mg mmol mg mmol mg mmol % 
[Pt(1S,2S)-(+)-diaminocyclohexane)Cl2] 110.0 0.27 29.8 0.26 74.0 0.19 74.6 
[Pt(1R,2R)-(-)-diaminocyclohexane)Cl2] 105.8 0.25 28.9 0.25 75.2 0.20 76.1 
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2.3.3. One pot synthesis of symmetric [Pt(PL)2]Cl2 complexes (PL = polyaromatic 
ligand) 
K2PtCl4 was weighed into a dry microwave vessel. 2 equivalents of the desired 
polyaromatic ligand was then added to the vessel and suspended in H2O (20 mL). The 
reaction mixture was then microwaved for 60 minutes at 180 °C using a CEM Discover 
SP microwave reactor. The vessel was then allowed to cool, resulting in a dark yellow 
solution. The reaction mixture was filtered to remove any unreacted ligand. The filtrate 
was then eluted through a Sep-pak C18 (20 cc, 5g) column to separate any unreacted 
K2PtCl4 starting material still present in solution. Individual reagent masses and yields 
are reported in Table 2.3. NMR characterisation data is reported in Table 2.5 
Table 2.3 Yields of symmetric [Pt(PL)2]Cl2 complexes. 
 Starting materials Product 
Complex K2PtCl4 Ligand  
mg mmol mg mmol mg Mmol % 
[Pt(1,10-phenanthroline)2]Cl2 27.6 0.07 25.0 0.14 38.2 0.06 91.7 
[Pt(4,7-dimethyl-1,10-phenanthroline)2]Cl2 47.0 0.11 51.2 0.23 64.4 0.09 84.4 
[Pt(5,6-dimethyl-1,10-phenanthroline)2]Cl2 40.2 0.10 41.7 0.20 61.4 0.09 90.0 
[Pt(3,4,7,8-tetramethyl-1,10-phenanthroline)2]Cl2 33.2 0.08 38 0.16 52.1 0.07 88.2 
[Pt(4,4′-dimethyl-2,2′-bipyridine)2]Cl2 38.9 0.09 34.7 0.19 51.0 0.08 85.8 
 
2.3.4. Microwave assisted synthesis of [Pt(1,10-phenanthroline)(3,4,7,8-
tetramethyl-1,10-phenanthroline)]Cl2 
[Pt(3,4,7,8-tetramethyl-1,10-phenanthroline)Cl2] was weighed into a dry microwave 
vessel. 1 equivalent of 1,10-phenanthroline was then added to the vessel and 
suspended in H2O (7.5 mL). The reaction mixture was then microwaved for 60 minutes 
at one of the following temperature ranges: 120, 150 or 180 °C using a CEM Discover 
SP microwave reactor. The vessel was then allowed to cool, resulting in a dark orange 
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solution. The solution was loaded onto a Biotage SNAP KP-C18-HS (30 g) column and 
eluted at 8 mL min-1 using a water to methanol gradient as reported in Table 2.4. Yield: 
35.0 mg, 32.4%. 
2.3.5. One pot synthesis of [Pt(1,10-phenanthroline)(3,4,7,8-tetramethyl-1,10-
phenanthroline)]Cl2 
K2PtCl4 was weighed into a dry microwave vessel. 1 equivalent of 1,10-phenanthroline 
and 3,4,7,8-tetramethyl-1,10-phenanthroline was then added to the vessel and 
suspended in H2O (7.5 mL). The reaction mixture was then microwaved for 60 minutes 
at 180 °C using a CEM Discover SP microwave reactor. The vessel was then allowed 
to cool, resulting in a dark orange solution. The solution was loaded onto a Biotage 
SNAP KP-C18-HS (30 g) C18 column and eluted at 8 mL min-1 using a water to 
methanol gradient as reported in Table 2.4. Yield: 38.1 mg, 34.8%. 
2.3.6. Synthesis of [Pt(1,10-phenanthroline)(4,7-dimethyl-1,10-
phenanthroline)]Cl2 
An equimolar ratio of the complexes [Pt(1,10-phenanthroline)2]Cl2 and [Pt(4,7-
dimethyl-1,10-phenanthroline)2]Cl2 were weighed into a dry microwave vessel and 
dissolved in H2O (7.5 mL). The reaction mixture was then microwaved for 15 minutes 
at 120 °C using a CEM Discover SP microwave reactor. The vessel was allowed to 
cool, resulting in a dark brown solution. The solution was loaded onto a Biotage SNAP 
KP-C18-HS (30g) column and eluted at 8 mL min-1 using a water to methanol gradient 





2.3.7. General syntheses of [Pt(4,7-diphenyl-1,10-phenanthroline)(PL)]Cl2 
complexes, (PL = polyaromatic ligand) 
2.3.7.1. Microwave assisted syntheses 
[Pt(PL)Cl2] was weighed into a dry microwave vessel. 1 equivalent of 4,7-diphenyl-
1,10-phenanthroline was added to the vessel and suspended in H2O (20 mL). The 
reaction mixture was microwaved for 60 minutes at 180 °C using a Biotage initiator 
microwave reactor. The vessel was then allowed to cool, resulting in a cloudy yellow 
solution. The solid was removed by vacuum filtration. The filtrate was then loaded onto 
a Biotage SNAP KP-C18-HS (30 g) column and eluted at 8 mL min-1 using a water to 
methanol gradient as reported in Table 2.4. 
2.3.7.2. Microwave assisted one pot syntheses 
K2PtCl4 was weighed into a dry microwave vessel. 1 equivalent of 4,7-diphenyl-1,10-
phenanthroline and 1 equivalent of the desired polyaromatic ligand was added to the 
vessel and suspended in H2O (20 mL). The reaction mixture was microwaved for 60 
minutes at 180 °C using a Biotage initiator microwave reactor. The vessel was then 
allowed to cool, causing a yellow solid to precipitate. The solid was removed by 
membrane filtration to collect a yellow filtrate. The filtrate was then loaded onto a 
Biotage SNAP KP-C18-HS (30 g) column and eluted at 8 mL min-1 using a water to 
methanol gradient as reported in Table 2.4. 
2.3.8. General Synthesis of [Pt(4,7-diphenyl-1,10-phenanthroline)(DACH)]Cl2 
complexes 
[Pt(DACH)Cl2] was weighed into a dry microwave vessel. 1 equivalent of 4,7-diphenyl-
1,10-phenanthroline was added to the vessel and suspended in H2O (20 mL). The 
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reaction mixture was microwaved for 60 minutes at 180 °C using a Biotage initiator 
reactor. The vessel was then allowed to cool, causing a brown solid to precipitate. The 
solid was removed by membrane filtration to collect a pale yellow filtrate. The filtrate 
was then loaded onto a Biotage SNAP KP-C18-HS (30 g) column and eluted at 
8 mL min-1 using a water to methanol gradient as reported in Table 2.4. 
Table 2.4 List of chromatography gradients for each complex. Example separation shown 
in Figure 2.2. 
Complex 
No. 
Chromatography gradient. Flowrate = 8 
mL/min. (1 Column volume = 33 mL) 
Run time 
(mins) 
1 0−40% MeOH gradient over 12 column volumes 49:30 
2 0−25% MeOH gradient over 15 column volumes 62:00 
3 0−40% MeOH gradient over 12 column volumes 49:30 
4 0−40% MeOH gradient over 15 column volumes 62:00 
5 0−45%  MeOH gradient over 12 column volumes 49:30 
6 10−45%  MeOH gradient over 12 column volumes 49:30 
7 10−50%  MeOH gradient over 10 column volumes 41:15 
8 10−50%  MeOH gradient over 10 column volumes 41:15 
9 10−50%  MeOH gradient over 10 column volumes 41:15 
10 10−50%  MeOH gradient over 10 column volumes 41:15 
11 0−50%  MeOH gradient over 15 column volumes 62:00 
12 0−50%  MeOH gradient over 15 column volumes 62:00 
Figure 2.2 Example separation of complex 4 including post run methanol flush. 
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Table 2.5 Summary of 1H and 1H-195Pt NMR data for microwave assisted synthesis of previously reported homoleptic complexes.68 










H2 9.21 (d, 4H, J = 5.5 Hz) 8.96  (d, 4H, J = 5.5 Hz) 9.11 (d, 4H, J = 5.4 Hz) 8.65 (s, 4H) 8.52 (d, 4H, J = 6.0 Hz) 
H3 7.90 (dd, 4H, J = 5.5, 8.1 Hz) 7.69 (d, 4H, J = 5.5 Hz) 7.87 (dd, 4H, J = 5.4, 8.3 Hz) 2.44 (s, 12H) 7.56 (d, 4H, J = 6.0 Hz) 
H4 8.79 (d, 4H, J = 8.1 Hz) 2.89 (s, 12H) 8.85 (d, 4H, J = 8.3 Hz) 2.79 (s, 12H) 2.58 (s, 12H) 
H5 8.09 (s, 4H) 8.18 (s, 4H) 2.74 (s, 12H) 8.25 (s, 4H) 8.16 (s, 4H) 
1H-195Pt 9.21 / -2246 8.96 / -2287 9.11 / -2287 8.65 / -2227 8.52 / -2259 
Figure 2.3 Structure of synthesised homoleptic complexes with four-fold symmetry indicated.
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2.4. Characterisation data for heteroleptic complexes (1-12) 
2.4.1. [Pt(1,10-phenanthroline)(3,4,78-tetramethyl-1,10-phenanthroline)]Cl2 (1) 
Yield: 35.0 mg, 32.4%. One pot yield: 38.1 mg, 
34.8%. 1H NMR (400 MHz, D2O): δ = 9.16 (d, 2H, 
J = 5.5 Hz), 8.67 (d, 2H, J = 8.2 Hz), 8.63 (s, 2H), 
8.16 (s, 2H), 8.06 (s, 2H), 7.70 (dd, 2H, J = 5.5, 
8.2 Hz) 2.78 (s, 6H), 2.45 (s, 6H). 1H-195Pt HMQC 
NMR (400 / 86 MHz, D2O): δ = 9.16 / -2238, 8.63 
/ -2238. Electronic spectrum λmax (ε M-1cm-1): 226 
(62,900 ± 700), 276 (41,800 ± 400). HRMS (ESI TOF) m/z: [M]2+ calcd for 
C28H24N4195Pt2+: 305.5824; found: 305.5818. RP-HPLC, 10-50% over 15 mins, tR = 
10.4 mins. 
2.4.2. [Pt(4,7-dimethyl-1,10-phenanthroline)(1,10-phenanthroline)]Cl2  (2) 
Yield: 29.4 mg, 29.7%. 1H NMR (400 MHz, D2O): 
δ = 9.16 (d, 2H, J = 5.5 Hz), 9.00 (d, 2H, J = 5.6 
Hz), 8.77 (d, 2H, J = 8.1 Hz), 8.15 (s, 2H), 8.07 
(s, 2H), 7.85 (dd, 2H, J = 5.6, 8.1 Hz), 7.71 (d, 
2H, J = 5.5 Hz), 2.90 (s, 6H). 1H-195Pt HMQC 
NMR (400 / 86 MHz, D2O): δ = 9.16 / -2267, 9.00 
/ -2267. HRMS (ESI TOF) m/z: [M]2+ calcd for 
C26H20N4195Pt2+: 291.5668; found: 291.5671. RP-
HPLC, 10–50% over 15 mins, tR = 9.4 mins.  
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2.4.3. [Pt(4,7-diphenyl-1,10-phenanthroline)(1,10-phenanthroline)]Cl2  (3) 
Yield: 20.9 mg, 28.5%. One pot yield: 14.6 mg, 
17.1%. 1H NMR (400 MHz, D2O): δ = 9.25 (d, 4H, 
5.6 Hz), 8.71 (d, 2H, J = 8.2 Hz), 8.12 (s, 2H), 8.03 
(m, 6H), 7.55 (t, 2H, J = 7.1, 14.5 Hz), 7.44 (m, 
8H). 1H-195Pt HMQC NMR (400 / 86 MHz, D2O): δ 
= 9.25 / -2285. Electronic spectrum λmax 
(ε M- 1cm- 1): 225 (65,600 ± 800), 283 (42,600 ± 
400), 303 (43,700 ± 500). HRMS (ESI TOF) m/z: [M]2+ calcd for C36H24N4195Pt2+: 
353.5824; found: 353.5826. RP-HPLC, 10–50% over 15 mins, tR = 14.6 mins.  
2.4.4. [Pt(4,7-diphenyl-1,10-phenanthroline)(3,4,78-tetramethyl-1,10-
phenanthroline)]Cl2  (4) 
Yield: 25.1 mg, 30.7%. One pot yield: 26.2 mg, 
31.1%. 1H NMR (400 MHz, D2O): δ = 9.30 (d, 2H, 
J = 5.6 Hz), 8.81 (s, 2H), 8.21 (s, 2H), 8.09 (s, 
2H), 7.91 (d, 2H, 5.6 Hz), 7.63 (t, 2H, J = 7.4 Hz), 
7.52 (t, 4H, J = 7.4 Hz), 7.33 (d, 4H, J = 7.4 Hz), 
2.82 (s, 6H), 2.56 (s, 2H). 1H-195Pt HMQC NMR 
(400 / 86 MHz, D2O): δ = 9.30 / -2263, 8.81 / -
2263. Electronic spectrum λmax (ε M-1cm-1): 223 (60,700 ± 700), 284 (41,100 ± 600), 
300 (42,000 ± 600). HRMS (ESI TOF) m/z: [M]2+ calcd for C40H32N4195Pt2+: 381.6137; 





phenanthroline)]Cl2  (5) 
Yield: 31.4 mg, 30.7%. One pot yield: 19.7 mg, 
22.9%. 1H NMR (400 MHz, D2O): δ = 9.27 (d, 2H, 
J = 5.6), 9.08 (d, 2H, J = 5.6), 8.19 (s, 2H), 8.06 
(s, 2H), 7.97 (d, 2H, J = 5.6 Hz), 7.82 (d, 2H, J = 
5.6 Hz), 7.60 (t, 2H, J = 7.5 Hz), 7.49 (t, 4H, J = 
7.5 Hz), 7.35 (d, 4H, J = 7.5 Hz), 2.90 (s, 6H). 1H-
195Pt HMQC NMR (400 / 86 MHz, D2O): δ = 9.27 
/ -2284, 9.09 / -2282. Electronic spectrum λmax (ε M-1cm-1): 227 (55,900 ± 300), 281 
(40,400 ± 400), 303 (40,900 ± 300). HRMS (ESI TOF) m/z: [M]2+ calcd for 




Yield: 17.4 mg, 28.3%. One pot yield: 11.2 mg, 
16.5%. 1H NMR (400 MHz, D2O): δ = 9.27 (d, 2H, 
J = 5.6 Hz), 9.19 (d, 2H, J = 5.2 Hz), 8.92 (d, 2H, 
8.5 Hz), 8.05 (s, 2H), 7.99 (m, 4H), 7.60 (t, 2H, J 
= 7.5 Hz), 7.49 (t, 4H, J = 7.5 Hz), 7.37 (d, 4H, J 
= 7.5 Hz), 2.71 (s, 6H). 1H-195Pt HMQC NMR (400 
/ 86 MHz, D2O): δ = 9.27 / -2286, 9.19 / -2286. 
Electronic spectrum λmax (ε M-1cm-1): 228 (58,500 
± 900), 293 (43,700 ± 600). HRMS (ESI TOF) m/z: [M]2+ calcd for C38H28N4195Pt2+: 





Yield: 3.6 mg, 7.1%. One pot yield: 10.5 mg, 
12.8%. 1H NMR (400 MHz, D2O): δ = 9.34 (d, 1H, 
J = 5.5 Hz), 9.26 (d, 1H, J = 5.5 Hz), 9.21 (m, 2H), 
9.17 (d, 1H, J = 8.3 Hz), 8.87 (d, 1H, J = 8.3), 
8.42 (s, 1H), 8.19 (dd, 1H, J = 5.5, 8.3 Hz), 8.13 
(dd, 1H, J = 5.5, 8.3 Hz), 8.02 (m, 4H), 7.53 (m, 
2H), 7.42 (m, 8H). 1H-195Pt HMQC NMR (400 / 86 
MHz, D2O): δ = 9.34 / -2279, 9.26 / -2279, 9.21 / 
-2279. Electronic spectrum λmax (ε M-1cm-1): 228 (67,900 ± 900), 288 (47,800 ± 600), 
300 (46,700 ± 500). HRMS (ESI TOF) m/z: [M]2+ calcd for C36H23N435Cl 195Pt2+: 
371.0632, found: 371.0633 RP-HPLC, 10–50% over 15 mins, tR = 13.6 mins. 
2.4.8. [Pt(4,7-diphenyl-1,10-phenanthroline) (2,2′-bipyridine)]Cl2 (8) 
Yield: 12.6 mg, 20.4%. One pot yield: 8.3 mg, 
11.7%. 1H NMR (400 MHz, D2O): δ = 9.16 (d, 2H, 
J = 5.5 Hz), 8.92 (d, 2H, J = 5.6 Hz), 8.52 (m, 4H), 
8.06 (d, 2H, J = 5.8 Hz), 8.03 (s, 2H), 7.92 (m, 
4H), 7.55 (m, 10H). 195Pt (86 MHz, D2O): δ = -
2358 ppm. HRMS (ESI TOF) m/z: [M]2+ calcd for 
C34H24N4195Pt2+: 341.5824; found: 341.5816. RP-HPLC, 10–50% over 15 mins, tR = 
13.6 mins.  
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2.4.9. [Pt(4,7-diphenyl-1,10-phenanthroline)(4,4′-dimethyl-2,2′-bipyridine)]Cl2 (9) 
Yield: 20.3 mg, 22.0%. One pot yield: 12.7 mg, 
17.2%. 1H NMR (400 MHz, D2O): δ = 9.15 (d, 2H, 
J = 5.6 Hz), 8.71 (d, 2H, J = 6.0 Hz), 8.20 (s, 2H), 
8.09 (s, 2H) 8.00 (d, 2H, J = 5.6 Hz), 7.67 (d, 2H, 
J = 6.0 Hz), 7.61 (t, 2H), 7.53 (m, 8H), 2.58 (s, 
6H). 195Pt (86 MHz, D2O): δ = -2294 ppm. HRMS 
(ESI TOF) m/z: [M]2+ calcd for C36H28N4195Pt2+: 
355.5981; found: 355.5982. RP-HPLC, 10–50% over 15 mins, tR = 15.1 mins. 
2.4.10. [Pt(4,7-diphenyl-1,10-phenanthroline)(5,5′-dimethyl-2,2′-bipyridine)]Cl2 
(10) 
Yield: 18.3 mg, 21.0%. One pot yield: 12.4 mg, 
13.8%. 1H NMR (400 MHz, D2O): δ = 9.10 (d, 2H, 
J = 5.6 Hz), 8.55 (s, 2H), 8.30 (s, 4H), 8.01 (m, 
4H), 7.56 (m, 2H), 7.50 (m, 8H) 2.56 (s, 6H). 
HRMS (ESI TOF) m/z: [M]2+ calcd for 
C36H28N4195Pt2+: 355.5981; found: 355.5980. RP-






Yield: 46.5 mg, 62.6%. 1H NMR (400 MHz, D2O): 
δ = 8.92 (d, 2H, J = 5.6 Hz), 7.96 (s, 2H), 7.91 (d, 
2H, J =5.6 Hz), 7.54 (s, 10H), 2.75 (m, 2H), 2.23 
(m, 2H), 1.67 (m, 2H), 1.49 (m, 2H), 1.25 (m, 2H). 
1H-195Pt HMQC NMR (400 / 86 MHz, D2O): δ = 
8.92 / - 2827. Electronic spectrum λmax (ε M-1cm-
1): 228 (33300 ± 200), 291 (40700 ± 200). HRMS 
(ESI TOF) m/z: [M]2+ calcd for C30H30N4195Pt2+: 320.6059 found: 320.6052. SRCD 
spectrum λmax nm (mdeg.mol/L, H2O): 195 (-1.47), 210 (-1.57), 232 (0.29), 249 (-0.56), 
312 (-0.78). RP-HPLC, 10–50% over 15 mins, tR = 12.0 mins. 
2.4.12. [Pt(4,7-diphenyl-1,10-phenanthroline)(1R,2R-(−)-1,2-
Diaminocyclohexane)]Cl2 (12) 
Yield: 45.1 mg, 61.7%. 1H NMR (400 MHz, D2O): 
δ = 8.92 (d, 2H, J = 5.6 Hz), 7.97 (s, 2H), 7.92 (d, 
2H, J =5.6 Hz), 7.54 (s, 10H), 2.75 (m, 2H), 2.23 
(m, 2H), 1.67 (m, 2H), 1.49 (m, 2H), 1.25 (m, 2H). 
1H-195Pt HMQC NMR (400 / 86 MHz, D2O): δ = 
8.92 / - 2828. Electronic spectrum λmax (ε M-1cm-
1): 228 (33300 ± 100), 291 (40000 ± 100). HRMS 
(ESI TOF) m/z: [M]2+ calcd for C30H30N4195Pt2+: 320.6059 found: 320.6052. SRCD 
spectrum λmax nm (mdeg.mol/L, H2O): 195 (1.06), 210 (1.34), 232 (0.65), 250 (0.45), 
312 (0.76). RP-HPLC, 10–50% over 15 mins, tR = 12.1 mins. 
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2.5. NMR characterisation of heteroleptic complexes (1-12)  
Both one and two-dimensional NMR experiments were used to confirm synthesis and 
verify ligand coordination. Due to stability issues with several complexes, NMR spectra 
of purified complexes were performed in D2O. To minimise artefacts and the formation 
of additional peaks due to complex degradation, samples were analysed immediately 
following preparation. Where possible, 1H-195Pt or 195Pt experiments were used to 
confirm ligand coordination. For complexes 8 and 9, two dimensional 1H-195Pt spectra 
could not be obtained due to limited stability and solubility, however 195Pt spectra were 
obtained. Despite several attempts, the poor solubility and stability of 10 prevented a 
195Pt signal from being obtained.  
Each complex presented a unique challenge during characterisation due to the 
presence of various functional groups. All complexes except 7 exhibited two-fold 
symmetry, thus where applicable, peak assignments took this into account. Due to the 
high degree of structural similarity between ligands, 1H experiments did not provide 
sufficient information to differentiate between resonances. Consequently, two-
dimensional experiments were required to make definite peak assignments. For most 
complexes, COSY experiments provided sufficient information, allowing for 
resonances with similar or identical coupling to be identified based on correlation 
between coupled protons. In cases where multiple aromatic singlets or methyl 
resonances were present, additional NOSEY experiments were performed. Unlike a 
COSY, a NOSEY experiment allows through-space interactions between nearby 
protons to be observed, allowing for unknown resonances to be definitively assigned 
based on their interactions with protons which have been assigned through other 
means. Peak assignments are summarised in Tables 2.6–2.8.
37 
 
Table 2.6 1H and 195Pt NMR for complexes 1-5 in D2O at 298 K. Chemical shift (ppm), multiplicity and integration reported. Assignments 
based on molecule symmetry as per Figure 2.4. 
 Complex No. 
Label 1 2 3 4 5 
H2 8.63 (s, 4H) 9.00 (d, 2H) 9.25 (d, 2H) 9.30 (d, 2H) 9.27 (d, 2H) 
H3 2.45 (s, 6H) 7.71 (d, 2H) 8.03 (m, 6H) 7.91 (d, 2H) 7.97 (d, 2H) 
H4/Phenyl 2.78 (s, 6H) 2.90 (s, 6H) 7.55 (t, 2H) 
7.44 (m, 8H) 
7.63 (t, 2H) 
7.51 (t, 2H) 
7.33 (d, 4H) 
7.60 (t, 2H) 
7.52 (t, 2H) 
7.35 (d, 4H) 
H5 8.16 (s, 2H) 8.15 (s, 2H) 8.12 (s, 2H) 8.09 (s, 2H) 8.06 (s, 2H) 
H2′ 9.16 (d, 2H) 9.16(d, 2H) 9.25 (d, 2H) 8.81 (s, 2H) 9.08 (d, 2H) 
H3′ 7.70 (dd, 2H) 7.85 (dd, 2H) 8.03 (m, 6H) 2.56 (s, 6H) 7.82 (d, 2H) 
H4′ 8.67 (d, 2H) 8.77 (s, 2H) 8.71 (d, 2H) 2.82 (s, 6H) 2.90 (s, 6H) 
H5′ 8.06 (s, 2H) 8.07 (s, 2H) 8.03 (m, 6H) 8.21 (s, 2H) 8.19 (s, 2H) 
1H-195Pt 9.16 / - 2238 
8.63 / - 2238 
9.16 / - 2265  
9.00 / - 2265 
9.25 / - 2285 9.30 / -2263 
8.81 / -2263 
9.27 / - 2282  
9.09 / - 2282 
Figure 2.4 Complexes 1-5 with symmetry indicated. 
1 2 3 4 5 
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Table 2.7 1H and 195Pt NMR for complexes 6-10 in D2O at 298 K. Chemical shift (ppm), multiplicity and integration reported. Assignments 
based on molecule symmetry for complexes 6, 8, 9 and 10 as per Figure 2.5. Protons H6′-H9′ for complex 7 assigned separately due to asymmetry 
of 5-chloro-1,10-phenanthroline ligand.  
 Complex No. 
Label 6 7 8 9 10 
H2 9.27 (d, 2H) 9.21 (d. 2H) 9.16 (d, 2H) 9.15 (d, 2H) 9.10 (d, 2H) 
H3 8.92 (m, 4H) 8.03 (dd, 2H) 8.06 (d, 2H) 8.00 (d, 2H) 8.01 (m, 4H) 
Phenyl 7.60 (t, 2H) 
7.49 (t, 2H) 
7.37 (d, 4H) 
7.53 (m, 2H) 
7.42 (m, 8H) 
7.55 (m, 10H) 7.61 (t, 2H) 
7.53 (m, 8H) 
7.56 (m, 2H) 
7.50 (d, 8H) 
H5 8.05 (s, 2H) 7.99 (s, 2H) 8.03 (s, 2H) 8.20 (s, 2H) 8.01 (m, 4H) 
H2′ 9.19 (d, 2H) 9.34 (d, 1H) 8.92 (d, 2H) 8.71 (d, 2H) 8.55 (d, 2H) 
H3′ 7.99 (m, 4H) 8.19 (d, 1H) 
 
7.92 (d, 2H) 7.67 (d, 2H) 2.56 (s, 6H) 
H4′ 7.99 (d, 2H) 9.17 (d, 1H) 8.52 (m, 4H) 2.58 (s, 6H) 8.30 (s, 4H) 
H5′ 2.71 (s, 6H) - 8.52 (m, 4H) 8.09 (s, 2H) 8.30 (s, 4H) 
H6′ - 8.42 (s, 1H) - - - 
H7′ - 8.87 (d, 1H) - - - 
H8′ - 8.13 (d, 1H) - - - 
H9′  9.26 (d, 1H)    
1H-195Pt 9.27 / - 2286 
9.19 / - 2286 
9.34 / - 2279 
9.26 / -2279 
9.21 / -2279 




Figure 2.5 Chemical structure of Complexes 1-6 with symmetry indicated. 
Table 2.8  1H and 195Pt NMR for complexes 11 and 12 in D2O at 298 K. Chemical shift (ppm), multiplicity and integration reported. 
Assignments based on molecule symmetry as per Figure 2.6. 
 Complex No. 
Label 11 12 
H2 8.92 (d, 2H) 8.92 (d, 2H) 
H3 7.96 (s, 2H) 7.97 (s, 2H) 
Phenyl 7.54 (s, 10H) 7.54 (s, 10H) 
H5 7.91 (d, 2H) 7.92 (d, 2H) 
H1′ 2.75 (m, 2H) 2.75 (m, 2H) 
H2′ 
1.49 (m, 2H) 
2.23 (m, 2H) 
1.49 (m, 2H) 
2.23 (m, 2H) 
H3′ 
1.25 (m, 2H) 
1.67 (m,2H) 
1.25 (m, 2H) 
1.67 (m,2H) 
1H-195Pt 8.92 / -2287 8.92 / -2287 
6 7 8 9 10 
11 
12 




2.5.1. [Pt(1,10-phenanthroline)(3,4,78-tetramethyl-1,10-phenanthroline)]Cl2 (1) 
Proton assignments for complex 1 accounted for symmetry as per Figure 2.7. Due to 
proximity to the coordinated nitrogens, both H2 and H2′ were expected to be relatively 
deshielded, thus H2′ was assigned to the doublet at 9.16 ppm (J = 5.5 Hz), whereas 
H2 was assigned to the singlet at 8.63 ppm. The doublet of doublets at 7.70 ppm was 
assigned to H3′, as this coupled with H2′ (J = 5.5 Hz). H4′ was assigned to the doublet 
at 8.67 ppm, as this coupled with H3′ (J = 8.2 Hz). To differentiate the remaining 
protons, a NOSEY experiment was required (Figure 2.8). H5′ was assigned to the 
singlet at 8.06 ppm, which observed a crosspeak with H4′. H5 was assigned to the 
resonance at 8.16 ppm which correlated with the methyl resonance 2.78 ppm; this 
resonance was thus identified to be H4. The remaining methyl group H3 was assigned 
to the singlet at 2.45 ppm, which displayed a NOSEY crosspeak with H2 at 8.63 ppm.  
Figure 2.7 Assigned 1H spectra of complex 1 in D2O at 298 K. Inserts: the 0–10 ppm 
spectrum and the structure with two-fold symmetry indicated. 
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Figure 2.8 Assigned NOSEY spectra of complex 1 in D2O at 298 K. Insert: Structure with 
two-fold symmetry indicated. 
2.5.2. [Pt(1,10-phenanthroline)(4,7-dimethyl-1,10-phenanthroline)]Cl2 (2) 
Due to difficulties in the purification of this complex, there were several minor aromatic 
impurities apparent in the spectrum, however, the major chemical shifts evident 
supported that the compounded had been successfully synthesised (Figure 2.9). H3′ 
was assigned to the doublet of doublets at 7.85 ppm, characteristic of the 1,10-
phenanthroline ligand. Due to equivalent J coupling values between the remaining 
doublets, a COSY experiment was performed (Figure 2.10). H2′ and H4′ were 
assigned to the doublets at 9.16 and 8.77 ppm, respectively, as they both observed 
crosspeaks with H3′. H2 was assigned to the doublet at 9.00 ppm (J = 5.6 Hz), which 
coupled with the doublet H3 at 7.71 ppm in the COSY. The singlets in the aromatic 
region at 8.15 and 8.07 ppm were assigned to H5 and H5′, respectively. This 
assignment was determined by a NOSEY experiment, where a correlation was 
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observed between the resonance at 8.07 ppm and H4′. The remaining resonance at 
2.90 ppm was assigned to the methyl in position H4. 
Figure 2.9 Assigned 1H spectra of complex 2 in D2O at 298 K. Inserts: the 0–10 ppm 
spectrum and the structure with two-fold symmetry indicated. 
Figure 2.10 Assigned COSY spectra of complex 2 in D2O at 298 K. Insert: Structure with 
two-fold symmetry indicated.  
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2.5.3. [Pt(4,7-diphenyl-1,10-phenanthroline)(1,10-phenanthroline)]Cl2 (3) 
For complex 3, several protons were found to have overlapping chemical shifts (Figure 
2.11). Protons H2 and H2′ coincided at 9.25 ppm to form a doublet integrating for four 
protons. From the COSY spectra, this doublet was found to couple with the multiplet 
at 8.03 ppm. As this multiplet integrated for six protons, this was determined to be an 
overlap of both H3 and H3′ with an additional resonance. As H4′ was identified to be 
doublet at 8.87 ppm by the COSY, this suggested H5 or H5′ coincided with the 
aforementioned multiplet. H5 was assigned to the singlet at 8.12 ppm, and H5′ the 
multiplet at 8.03 ppm, respectively. This assignment was based on the deshielding 
effect of the phenyl group, which would shift the resonance for H5 further downfield. 
Attempts to clarify this by means of NOSEY spectra were attempted, however were 
unsuccessful due to stability issues with the complex. The remaining triplet at 
7.55 ppm and the multiplet at 7.44 ppm were assigned to the phenyl ring. 
Figure 2.11 Assigned 1H spectra of complex 3 in D2O at 298 K. Inserts: the 0–10 ppm 





For this complex, the most deshielded protons H2 and H2′ were easily differentiated 
by their multiplicity (Figure 2.12). H3 was assigned to the resonance at 7.91 ppm as 
this was observed to couple with H2 (J = 5.6 Hz). As H5 and H5′ could not be 
differentiated by a COSY, a NOSEY NMR experiment was used to resolve these 
signals. H5′ was identified to be the singlet at 8.21 ppm, which exhibited a cross peak 
with the methyl in position H4′ at 2.82 ppm. As the resonance at 8.09 ppm displayed 
no cross peaks with a methyl, this was assigned to H5. Interestingly, the phenyl 
protons split into three components. Protons c and b were assigned to the triplets at 
7.63 and 7.52 ppm, respectively. Proton a was assigned to the doublet at 7.33 ppm. 
The remaining resonance at 2.56 ppm was observed to have a NOSEY cross peak 
with H2′, and thus was assigned to the methyl in the H3′ position.  
Figure 2.12 Assigned 1H spectra of complex 4 in D2O at 298 K. Inserts: the 0–10 ppm 





Assignments for complex 5 were illustrated in Figure 2.13. Due to similar chemical 
shifts and identical coupling, the doublet resonances could not be assigned to a 
particular ligand based on 1H or COSY experiments. Consequently, a NOSEY 
experiment was performed. H3′ was assigned to the doublet at 7.82 ppm, as it 
observed a crosspeak with the methyl resonance at 2.90 ppm. This then allowed for 
H2’ to be assigned to the doublet at 9.08 ppm by the COSY. Similarly, the remaining 
doublets at 9.27 and 7.97 ppm were assigned to H2 and H3, respectively. The singlet 
at 8.19 ppm was then assigned to H5′ as this displayed a NOSEY cross peak with the 
methyl resonance at 2.90 ppm. The singlet at 8.06 ppm was thus assigned to H5 by 
process of elimination. The splitting for the phenyl peaks was analogous to complex 
4, thus these protons were assigned similarly. 
Figure 2.13 Assigned 1H spectra of complex 5 in D2O at 298 K. Inserts: the 0–10 ppm 





Much like complex 3, complex 6 exhibited overlapping resonances (Figure 2.14). Both 
H3 and H3′ overlapped to form a multiplet integrating for four protons at 7.99 ppm. 
This overlap of H3 and H3′ meant that the identity of H2 and H2′ could not be clarified 
by means of NOSEY. Thus, taking into account the deshielding effect of the phenyl 
ring, and prior observations of complex 5, H2 was assigned to the doublet at 9.27 ppm, 
and H2′ to the remaining doublet at 9.19 ppm. H4′ was assigned to the doublet at 8.92 
ppm which coupled with H3′ in the COSY. The singlet at 8.05 ppm was assigned to 
H5. Again, the phenyl peaks split into three components, thus peak assignments 
followed prior observations. The remaining singlet at 2.71 ppm was assigned to the 
methyl group on the H5′ position. 
Figure 2.14 Assigned 1H spectra of complex 6 in D2O at 298 K. Inserts: the 0–10 ppm 
spectrum and the structure with two-fold symmetry indicated. 
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2.5.7. [Pt(4,7-diphenyl-1,10-phenanthroline)(5-chloro-phenanthroline)]Cl2 (7) 
[Pt(4,7-diphenyl-1,10-phenanthroline)(5-chloro-phenanthroline)]Cl2 was the only 
complex with an asymmetric ligand and prone to degradation. Consequently, complex 
7 proved to be difficult to characterise. When the initial sample was analysed, the 
proton spectra indicated that the complex was formed, with the total integration 
conforming to expectations. However, when attempting longer experiments, such as 
a 1H-195Pt or NOSEY, the spectra obtained were relatively noisy and the obtained 
signals were quite low. Fortunately, after preparing a fresh sample, an adequate 
COSY spectra was obtained. By overlaying the 1H spectra obtained prior across the 
F1 and F2 dimension, clear peak assignments based on coupling were able to be 
made (Figure 2.15). Interestingly, there was some pseudo-symmetry in the molecule 
due to the presence of the symmetric 4,7-diphenyl-1,10-phenanthroline ligand, thus 
the protons further away from the platinum centre were relatively simple to assign. 




Assignments for complex 7 were indicated in Figure 2.16. Due to the symmetry of the 
4,7-diphenyl-phenanthroline ligand, these peaks were assigned first. The phenyl 
peaks were observed at 7.53 and 7.42 ppm, integrating for a total of 10 protons, 
although these peaks were notably less sharp than in other samples. The resonances 
for H5, H6, H3 and H8 appeared to overlap, however the characteristic doublet of 
doublets for H3 and H8 could still be observed at 8.03 ppm, and the singlet for protons 
H5 and H6 at 7.99 ppm. This was confirmed by COSY NMR, as this multiplet was 
observed to only exhibit coupling with protons H2 and H9 at 9.21 ppm. The doublet of 
doublet at 8.13 ppm was assigned to H8′, as this proton being further away from the 
chlorine atom would be more upfield compared to H3′. Being closer to the chlorine 
atom, and thus more deshielded, H3′ was assigned to the doublet of doublet at 
8.19 ppm. The singlet at 8.42 ppm was assigned to H6′, as this integrated to one 
proton as expected. The doublet at 8.87 ppm was assigned to H7′ as this resonance 
was observed to couple with H8′. Protons H2, H9, H4′ and H9′ appeared to overlap, 
however they could still be distinguished. H4′ was assigned to the doublet at 9.17 ppm, 
as it coupled with H3′ in the COSY spectra. Protons H2 and H9 appeared to overlap 
at 9.22 ppm, thus COSY was used to confirm their identity, as they were observed to 
couple with protons H3 and H8. The doublet at 9.26 ppm was assigned to H9′, as 
coupling was observed with H8′ in the COSY. Finally, the doublet at 9.34 ppm was 
assigned to H2′, as it exhibited coupling with H3′ in the COSY NMR. 
2.5.8. [Pt(4,7-diphenyl-1,10-phenanthroline)(2,2′-bipyridine)]Cl2 (8) 
Complex 8 proved to be one of be the least stable complexes synthesised, with minor 
degradation peaks being observable immediately. Over time, a fine yellow precipitate 
began to form. Consequently, attempts to obtain a 1H-195Pt spectra were unsuccessful, 
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however, a one-dimensional platinum was acquired, confirming the presence of a 
platinum metal centre (Figure 2.17). 
Figure 2.16 Assigned 1H spectra of complex 7 in D2O at 298 K. Inserts: the 0–10 ppm 
spectrum and complex structure. 
Figure 2.17 195Pt spectra of complex 8 in D2O at 298 K. Insert: Complex structure with two-
fold symmetry indicated.  
0.5 mg  
in 450 µL 
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H2 and H2′ were assigned based on prior observations (Figure 2.18). H3 and H3′ were 
then assigned by means of COSY. Interestingly, whilst the resonance for H3′ at 
7.92 ppm would be expected to form a clear doublet of doublets, the peak appeared 
to be truncated, thus coupling constants could not be determined. This was likely an 
artefact caused by improper shimming, due to almost immediate precipitation of the 
complex.71 Several attempts were made to acquire a well-shimmed spectra, however, 
rapid degradation of this complex in solution proved to be a barrier. H5 was assigned 
to the singlet at 8.03 ppm. The resonances for H4′ and H5′ appeared to overlap at 8.52 
ppm. This was determined to be the case as the only additional coupling observed in 
the COSY was with H3′. For complex 8, the phenyl peaks formed a broad multiplet at 
7.55 ppm. 
Figure 2.18 Assigned 1H spectra of complex 8 in D2O at 298 K. Inserts: the 0–10 ppm 
spectrum and the structure with two-fold symmetry indicated. 
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2.5.9. [Pt(4,7-diphenyl-1,10-phenanthroline)(4,4′-dimethyl-bipyridine)]Cl2 (9) 
Much like complex 8, complex 9 also appeared to degrade in a similar manner thus 
only a proton and COSY spectra were obtained. Similar issues were encountered 
when attempting to obtain a 1H-195Pt spectra, thus a 195Pt spectra 1D spectra was 
conducted. Despite a long experiment (~ 5 hours), only a small peak at -2294 ppm 
was observed. In addition, a unique observation was made when obtaining 1H spectra 
at various concentrations. Due to solubility limitations, an initial 0.5 mg NMR sample 
was prepared. With this initial sample, the expected splitting was not observed. 
Instead, several of the characteristic doublet peaks appeared as triplets, and one of 
the expected singlet peaks manifested as a doublet (Figure 2.19). When the 
concentration was halved, the expected splitting was observed, along with a minor 
downfield shift belonging to several of the aromatic peaks. Similar phenomena 
involving concentration dependant π-stacking interactions have been reported for 
Co(III) and Ru(II) molecules incorporating large planar ligands.72, 73  




0.5 mg  
in 450 µL 
0.25 mg 
in 450 µL 
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With the coupling issue resolved, assignments followed Figure 2.20. H2 and H2′ were 
assigned based on prior observations, and subsequently H3 and H3′ by COSY 
experiment. The methyl group in position H4′ was easily assigned to the singlet at 
2.58 ppm. For complex 9, the phenyl peaks were observed to split into two 
components at 7.61 and 7.53 ppm. As the stability of this complex prohibited the 
acquistion of a NOSEY spectrum, the singlets at 8.20 and 8.09 ppm were assigned to 
H5 and H5′, respectively. This was based on the deshielding effect of the phenyl ring, 
and the shielding effect of the methyl groups. This assignment was further reinforced 
by comparison of the diluted and undiluted NMR samples. In both samples, H5 
appeared as a singlet, however in the more concentrated sample, H5′ was observed 
as a doublet. This change in splitting patterns is attributed to unique π-stacking effects. 
Due to the presence of the bulky phenyl substituents, it is hypothesised H5 is sterically 
blocked from stacking, thus the multiplicity remained the same.  
Figure 2.20 Assigned 1H spectra of complex 9 in D2O at 298 K. Inserts: the 0–10 ppm 





Complex 10 also proved to be difficult in obtaining a clear spectra, as this complex 
was sparsely soluble in D2O. Although this particular complex was highly soluble in 
MeOD and DMSO-d6, it appeared to rapidly decompose when dissolved in these 
solvents, forming a yellow precipitate. An example spectrum of 10 in methanol is seen 
in Figure 2.21. As this complex was also not stable in D2O, only proton and COSY 
spectra could be obtained.  





Proton assignments were as illustrated in Figure 2.22. H2 and H2′ were assigned 
based on prior observations. H3 was assigned to the multiplet integrating at 8.01 ppm, 
as this observed a COSY crosspeak with H2. Strangely, no further coupling was 
observed in the COSY. This suggested that the resonances for H4′ and H5′ overlapped 
to form the singlet at 8.30 ppm, which integrated for four protons. By process of 
elimination, H5 must form part of the multiplet at 8.01 ppm. In comparison, for all the 
other complexes incorporating 4,7-diphenyl,1-10-phenanthroline, H5 was typically 
observed further downfield relative to H5′. It is possible that this difference may be as 
a result of the positioning of the methyl groups. As they are relatively close to the 
nitrogens, their electron donating effect may be significantly diminished. Similar to 
complex 9, the phenyl protons split into two components and thus were assigned to 
the resonances at 7.56 and 7.50 ppm. The methyl in position H3′ was assigned to the 
singlet at 2.56 ppm. 
Figure 2.22 1H spectra of complex 10 in D2O at 298 K. Inserts: the 0–10 ppm spectrum and 




enantiomers; S,S (11) and R,R (12) 
As there were only minor differences between the 1H spectra for the enantiomers 11 
and 12, peak assignments were made based on the spectra for complex 11 (Figure 
2.23). The aromatic resonances for the 4,7-diphenyl-phenanthroline ligand were 
simple to assign (see appendix Figure A.50). The diamminocyclohexane protons were 
assigned using the COSY. Due to a lack of coherent splitting, the axial and equatorial 
protons could not be differentiated, thus the diamminocyclohexane resonances were 
reported as multiplets. H1′ was assigned to the multiplet at 2.75 ppm. The H2′ protons 
were assigned to be the multiplets at 2.23 and 1.49 ppm, and H3′ protons assigned to 
the multiplets at 1.67 and 1.25 ppm.  
Figure 2.23 1H spectra of complex 11 in D2O at 298 K. Inserts: the 0–10 ppm spectrum and 




2.6. Results and Discussion 
2.6.1. Reflux synthesis of [Pt(PL)2]Cl2 complexes 
The synthesis of [Pt(4,7-diphenyl-,1-10-phenanthroline)(1,10-phenanthroline)]2+ was 
initially based upon a modified literature method.67 [Pt(1,10-phenanthroline)Cl2] 
(0.1 mmol) and the ligand 4,7-diphenyl-1,10-phenanthroline (0.1 mmol) were 
suspended in a mixed solution of 1:1 H2O and ethylene glycol (100 mL). Despite a 
large volume of solvent relative to the literature method, and the application of reflux 
conditions, the reagents did not fully dissolve. In an attempt to address this solubility 
issue, the total solvent volume was increased to 200 mL, however the solution still did 
not become homogenous (Figure 2.24).  
Figure 2.24 Example of solubility issue encountered under reflux conditions. 
Consequently, this prompted the use of higher boiling point solvents such as 
dimethylformamide (DMF) and dimethyl-sulfoxide (DMSO) to aid in solubilising the 
start materials. Both solvents were able to solubilise ample amounts of the ligand and 
[Pt(1,10-phenanthroline)Cl2] under reflux conditions, even when using solvent 
volumes as low as 25 mL. However, isolation of any potential products was 
unsuccessful, as all of the crude reaction components appeared to be highly soluble 
even at room temperature. As these solvents could not be removed by rotary 
evaporation, isolation was not possible despite attempted product precipitation. 
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Consequently, the reaction was repeated using a mixed solution of DMSO or DMF in 
H2O. Through several trials it was found that a 1:9 mixture of DMSO or DMF in H2O 
(50 mL) was sufficient to maintain solubility of the starting materials (~0.1 mmol) under 
reflux conditions. Once each reaction appeared to have reached completion based on 
HPLC analysis, they were allowed to cool, in both cases forming a yellow precipitate 
and yellow filtrate. 1H NMR analysis of the precipitate identified it to be predominantly 
[Pt(1,10-phenanthroline)Cl2].  
Isolation of the product continued to be problematic, as it was soluble in both DMSO 
and H2O. In an attempt to precipitate the product, saturated potassium 
hexafluorophosphate (KPF6) was added. As PF6 salts are typically soluble in both DMF 
and DMSO, the reaction mixture was first diluted with H2O (150 mL) before the addition 
of excess KPF6, and then the solution was left to sit for 24 hours. No precipitate formed 
from the diluted DMF reaction, however a very small amount of precipitate formed in 
the diluted DMSO reaction. This solution was left to sit for an additional 72 hours, with 
no further change. Approximately 1 mg of precipitate was collected and dissolved in 
DMSO-d6 for NMR analysis. 1H NMR indicated that the desired product was present 
although there was a significant amount of both starting material and residual DMSO.  
Due to the issues encountered using DMSO and DMF, the use of H2O and ethylene 
glycol was revisited. Relative to initial testing, batch sizes were reduced significantly 
(<0.25 mmol), and the solvent ratios adjusted to a 3:7 H2O to ethylene glycol ratio 
(60:140 mL). By increasing the glycol ratio, a higher reflux temperature was achieved, 
which resulted in a notable improvement in solubility. Despite this, reaction times were 
quite prolonged, often exceeding 72 hours. Upon cooling of the reaction mixture, a 
moderate amount of starting material precipitated, which was removed by vacuum 
filtration to collect a yellow filtrate. Since such a large volume of glycol could not be 
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removed by rotary evaporation, the glycol containing filtrate was diluted with a large 
amount of H2O (300 mL). Saturated potassium hexafluorophosphate (KPF6) was then 
added, causing a moderate amount of brown solid to precipitate. It was expected that 
the collected precipitate would be predominantly the heteroleptic complex with trace 
amounts of starting material. Surprisingly, 1H and COSY NMR of the PF6 salt indicated 
the presence of several components in similar ratios (Figure 2.25.).  
Figure 2.25 COSY spectrum of crude Pt(4,7-diphenyl-1,10-phenanthroline)(1,10-
phenanthroline)](PF6)2 sample in CD3CN. 
A prolonged 1H-195Pt experiment performed over 8 hours acquired no signal, therefore 
ligand coordination was not confirmed. Subsequent HPLC analysis of the crude 
sample identified 3 components of similar peak intensity. Flash column 
chromatography with an ACN:H2O mobile phase  was used in an attempt to separate 
these components using a Sep-pak C18 (5 g) cartridge in conjunction with a Biorad 
pump and UV-Vis detector and. Despite the use of various solvent ratios, adequate 
separation could not be achieved, and the identity of the components remained 
unknown.   
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2.6.2. Identification of the products formed 
In the literature, complexes of the structure [Pt(PL)2]2+ have been reported to be 
relatively stable. Given that the ligand and [Pt(PL)Cl2] starting materials are relatively 
water insoluble, it would be expected that an aliquot of the reaction mixture post 
filtration would consist mostly of the heteroleptic complex, with some starting material. 
As discussed earlier the HPLC traces indicated three main components, and 1H NMR 
similarly observed multiple peaks with similar chemical shifts. Due to the sparing 
solubility of the starting materials, this strongly suggested that some other product was 
forming.  
Thus, to discern the identity of each component, high resolution ESI-MS was 
performed on a sample of the crude reaction mixture of [Pt(4,7-diphenyl-,1-10-
phenanthroline)(1,10-phenanthroline)]2+. Interestingly, it was found that three 
complexes had formed; [Pt(4,7-diphenyl-1,10-phenanthroline)2]2+, [Pt(1,10-
phenanthroline)2]2+, and [Pt(4,7-diphenyl-,10-phenanthroline)(1,10-phenanthroline)]2+ 
as shown in Figure 2.26. 
Figure 2.26 ESI-MS spectrum of crude [Pt(4,7-diphenyl-,1-10-phenanthroline)(1,10-
phenanthroline)]2+ reaction mixture. 
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Subsequent review of the literature did not indicate that phenanthroline ligands would 
be highly labile when coordinated to platinum. However, several studies document the 
lability of phenanthroline ligands when coordinated to copper(I).74-77 Relative to Pt(II) 
complexes, Cu(I) complexes are much more labile in solution. In most cases, this 
lability results in rapid ligand exchange, leading to formation of the most 
thermodynamically preferred complex.76  
A study by Schmittel et. al78 reported that several complexes incorporating the ligands 
1,10-phenanthroline and 4,7-diphenyl-1,10-phenanthroline exhibited no clear 
preference for formation of either the heteroleptic or homoleptic complexes. To 
overcome this issue, the 2 and 9 positions were arylated to sterically hinder the 
formation of the more stable homoleptic complex. In the context of platinum 
complexes, 2,9 substituted phenanthrolines are much more sterically hindered due to 
the larger metal centre, therefore preventing the coordination of a second polydentate 
ligand.79, 80 Therefore, using current techniques, the preferential formation of a 
heteroleptic bis-phenanthroline complex cannot readily be controlled. 
2.6.3. Optimising microwave synthesis conditions using [Pt(1,10-
phenanthroline) (3,4,7,8-tetramethyl-1,10-phenanthroline)]Cl2 
As discussed prior, the poor solubility of the reagents required to form the complex 
[Pt(4,7-diphenyl-1,10-phenanthroline)(1,10-phenanthroline)]2+ under reflux conditions 
was problematic. To improve both the rate of reaction and product yields, microwave 
assisted syntheses were investigated. Microwave reactors have seen extensive use 
in the field of organic synthesis,81-83 however their use in inorganic synthesis is notably 
less common. Nonetheless, microwave-assisted syntheses have been reported for the 
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anticancer drug cisplatin,84, 85 cycloplatinated complexes,86 metal-organic 
frameworks,87 and several other inorganic compounds.88, 89 
One of the main advantages of microwave synthesis is being able to heat a sample to 
temperatures beyond the boiling point of the chosen solvent.90 By significantly 
increasing the reaction temperature, reactions rates can be accelerated significantly 
according to the Arrhenius equation. To safely achieve higher temperatures a sealed 
vessel is used; as the sample heats the pressure will rise accordingly, thus the solvent 
will remain in the liquid phase. As most conventional microwave reactors do not have 
a homogenous magnetic field, the irradiated sample will experience localised 
hotspots.91, 92 Consequently, the use of a magnetic stir bar is vital to ensure the 
homogenous heating of both the sample and solvent. 
With this in mind, three temperatures were investigated: 120, 150 and 180 oC using a 
CEM Discover SP microwave reactor. The amounts of reagent were kept consistent 
between each experiment. In addition, the following variables were kept constant; a 
reaction time of 1 hour, stirring at 600 rpm and a solvent volume of 7.5 mL for all 
samples. Due to the higher cost of the 4,7-diphenyl-1,10-phenanthroline ligand 
(~$200/g), this was substituted by 3,4,7,8-tetramethyl-1,10-phenanthroline ($60/g). 
Not only was this ligand cheaper, the greater solubility of its respective homoleptic 
complex permitted a larger reaction scale during testing. Water was chosen as a 
solvent to minimise unwanted interactions with the platinum starting material (e.g. 
solvolysis by DMSO),93 whilst also allowing for easier extraction of the product. For 
the starting materials, [Pt(3,4,7,8-tetramethyl-1,10-phenanthroline)Cl2] was chosen 
instead of [Pt(1,10-phenanthroline)Cl2], as the yield for this platinum salt was typically 
higher. To avoid preferential formation of either homoleptic complex, a 1:1 ratio of 
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1,10-phenanthroline ligand to [Pt(3,4,7,8-tetramethyl-1,10-phenanthroline)Cl2] was 
used for all experiments.  
Each reaction was performed and HPLC analysis conducted upon reaction 
completion. The 120 oC reaction appeared to have a significant amount of unreacted 
starting material suspended in solution. This was to be expected, as apart from an 
increase in pressure slightly above atmospheric conditions, the temperature was 
relatively similar to previously tested reflux conditions. An aliquot of the reaction 
mixture (50 μL) was removed and diluted by a factor of ten for HPLC. This sample 
produced the same three-peak distribution characteristic of the reflux reaction, 
although the intensity was quite low. At 150 oC, there was visible improvement, 
however, there was still a moderate amount of unreacted starting material that settled 
at the bottom of the reaction vessel upon cooling. The HPLC showed the same 
distribution of products as the 120 oC reaction, however the peak intensities had 
increased. Unsurprisingly, the 180 oC reaction proved to be most effective, with no 
discernible solid remaining. HPLC analysis of a diluted aliquot of this reaction mixture 
also exhibited the same peak distribution, but with even greater peak intensities 
(Figure 2.27). An additional two-hour reaction was performed at 180 oC to determine 
if additional time would alter the reaction outcome, however there was only minimal 




Temperature Complex a Complex b Complex c 
120 OC - - - 
150 OC <1mg 6.0 mg, 5.3% <1 mg 



















Figure 2.27 Comparison of one hour reactions at three temperature ranges. 10–50% HPLC gradient over 15 minutes. Yields of individual components 
following purification reported above. 
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2.6.4. Isolation of heteroleptic complexes 
Despite several attempts, the reaction components could not be separated using the 
Biorad system. Due to the use of a relatively small C18 stationary phase (Sep-pak 
20 cc, 5 g cartridge), there appeared to be significant peak tailing, thus the complexes 
did not separate. Subsequently, a Biotage Isolera One flash chromatography system 
equipped with a larger C18 column was used. The first complex to be separated was 
[Pt(1,10-phenanthroline)(3,4,7,8-tetramethyl-1,10-phenanthroline)]Cl2, synthesised 
by a 180 oC microwave reaction. Prior to loading on the column, the crude sample was 
reduced to 2 mL. To avoid further complication, no KPF6 was added and the crude 
reaction mixture was loaded directly onto a Biotage SNAP Ultra C18 (12 g) column. 
The instrument was configured to a flow rate of 25 mL.min-1 with a solvent gradient of 
0–50% MeOH over 400 mL to reproduce the HPLC conditions. UV-Vis detection was 
configured to collect at 254 nm, with a low collection threshold of 15 mAU. Three main 
components were separated and each was rotary evaporated to dryness. 1H NMR 
analysis of the samples allowed identification of the components collected which 
eluted. [Pt(1,10-phenanthroline)2]Cl2 eluted first, followed by [Pt(1,10-
phenanthroline)(3,4,7,8-tetramethyl-1,10-phenanthroline)]Cl2 and then [Pt(3,4,7,8-
tetramethyl-1,10-phenanthroline)2]Cl2.   
This method was later modified for the purification of [Pt(4,7-diphenyl-1,10-
phenanthroline)(PL)]Cl2 complexes. All reactions produced three products, however, 
for syntheses incorporating the 4-7,diphenyl-1,10-phenanthroline ligand, the majority 
of the respective homoleptic complex precipitated as the reaction cooled. Due to poor 
overall solubilities, the crude reaction mixtures could not be reduced by rotary 
evaporation. This was an obstacle to purification using the Biotage SNAP Ultra C18 
(12 g) column as loading more than 4 mL at a time resulted in significant peak tailing, 
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leading to poor separation. To overcome this and minimise loss of product, a small 
aliquot of the reaction mixture was first loaded onto the 12 g column to develop a 
purification method. Once an effective method for separation was developed, the 
column was changed to a Biotage Ultra C18 (30 g) column and the gradient extended 
to accommodate for the larger column. Through numerous separations, it was 
determined that a maximum of 10 mL could be loaded whilst still maintaining good 
separation. Over the course of several runs, it was determined that reducing the flow 
rate to 8 mL.min-1 when using the 30 g column, as opposed to the instrument default 
of 25.mL min-1, greatly improved component separation. Flow rates slower than 
8 mL.min-1 were also investigated, however this significantly increased the runtime 
with little improvement in separation. For several of the more difficult to purify 
complexes, the UV-Vis collection threshold was raised to 75 mAU. Whilst this resulted 
in a loss of product, this minimised the collection of overlapped peaks. 
2.6.5. Investigating the need for a Pt(PL)Cl2 starting material 
From the investigated syntheses of heteroleptic phen or bipy complexes it was clear 
that there were typically three main complexes formed: the heteroleptic complex and 
the two homoleptic complexes, respective of the ligands. This lead to the idea that 
K2PtCl4 starting material could be reacted directly with 1 equivalent of each of the 
desired ligands under microwave conditions. Given the labile nature of the phen 
ligands, the distribution of products would be expected to be relatively similar. 
To first determine the feasibility of this method, the synthesis of several previously 
reported homoleptic complexes was undertaken using a CEM Discover SP microwave 
reactor. The following conditions were kept constant between each reaction: a solvent 
volume of 20 mL, reaction time of 1 hour, temperature of 180 oC and stirring at 
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600 rpm. The investigated complexes included: [Pt(1,10-phenanthroline)2]Cl2, [Pt(4,7-
dimethyl-1,10-phenanthroline)2]Cl2, [Pt(5,6-dimethyl-1,10-phenanthroline)2]Cl2, 
Pt(3,4,7,8-tetramethyl-10-phenanthroline)Cl2 and [Pt(4,4′-dimethyl-2,2′-
bipyridine)2]Cl2. Following synthesis, each complex was filtered to remove excess 
starting material then eluted through a Sep-pak C18 cartridge (20 cc, 5 g) to remove 
any remaining K2PtCl4. Surprisingly, this method proved to be quite effective, as all 
compounds were synthesised in relatively high yields and purity. Each complex was 
characterised as its chloride salt via 1H NMR, yielding the expected chemical shifts 
and coupling.68 1H-195Pt NMR confirmed bis-N,N′ coordination with chemical shifts at 
the ~-2300 ppm range. 
2.6.6. One pot synthesis of [Pt(1,10-phenanthroline)(3,4,7,8-tetramethyl-1,10-
phenanthroline)]Cl2 
Given the success in synthesising the aforementioned homoleptic complexes, 
[Pt(1,10-phenanthroline)(3,4,7,8-tetramethyl-1,10-phenanthroline)]Cl2 was 
investigated next. To allow comparison, K2PtCl4, 1,10-phenanthroline and 3,4,7-8-
tetramethyl-1,10-phenanthroline were weighed in molar ratios similar to the earlier 
microwave reactions which used [Pt(3,4,7,8-tetramethyl-1,10-phenanthroline)Cl2] and 
phen. The same conditions were used, including a 1-hour reaction time, temperature 
of 180 oC and H2O (7.5 ml) as the solvent.  
The HPLC for this reaction showed a similar peak distribution for the crude product as 
the earlier conventional synthesis, although the peaks were slightly broader and there 
was evidence of minor impurities (Figure 2.28). Despite this, the isolation of the 
heteroleptic complex was successful using the prior established 0–50% MeOH 
gradient in conjunction with a 12 g Biotage Ultra C18 column. Surprisingly, the final 
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yield of the isolated heteroleptic product (38.1 mg, 34.8%) was relatively close to that 
obtained via the traditional synthesis method (35.0 mg, 32.4%). 
 
Figure 2.28 HPLC comparison of traditional and one pot syntheses of complex 1. 
2.6.7. Comparison syntheses of [Pt(4,7-diphenyl-1,10-phenanthroline)(PL)]Cl2 
complexes 
To determine the optimal synthetic route for [Pt(4,7-diphenyl-1,10-
phenanthroline)(PL)]Cl2 complexes, two methods were investigated. Both reactions 
were performed under identical conditions These were based on prior investigation 
and were as follows: a reaction temperature of 180 oC, reaction time of 1 hour and 
20 mL of H2O as the solvent. Where possible, molar ratios of reagents were kept 
similar, although this was not possible during the one pot syntheses of complexes 
8 – 10 due to poor solubility of the bipy ligands.  
68 
 
The traditional synthesis method was performed first, from which 4-7-diphenyl-1,10-
phenanthroline was reacted with [Pt(PL)Cl2] to form the desired heteroleptic complex. 
This first required the [Pt(PL)Cl2] intermediate to be prepared; involving precipitation 
from DMSO over ~24 hours. Next, the one pot method was investigated, based on the 
earlier synthesis of [Pt(1,10-phenanthroline)(3,4,7,8-tetramethyl-1,10-
phenanthroline)]Cl2. Unlike the traditional synthesis method, reagents could be 
weighed out and then the reaction performed immediately.  
Surprisingly, yields between the two methods varied greatly. Contrary to the success 
of the one pot synthesis of complex 1, the average one pot yields for these complexes 
were lower. The was most notable for complexes 3, 8, and 10, where one pot yields 
were almost half relative to the traditional syntheses. However, for complexes 4 and 
7, the one pot yields obtained were higher. For complex 4, this was attributed to the 
electron donating methyl substituents on the 3,4,7,8-tetramethyl-phenanthroline 
ligand, contributing to greater stability and thus formation of the heteroleptic complex. 
For complex 7, the disparity in yield was attributed to the 5-chloro-phenanthroline 
ligand. When attempting to synthesise [Pt(5-chloro-1,10-phenanthroline)Cl2] the yield 
was very low relative to other [Pt(PL)Cl2] analogues, indicating that the formation of 
this intermediate was not favourable. By skipping this step, the one pot method 
increased yields of the heteroleptic complex, however the lower yield and poor stability 
indicated that the formation of this complex was not favourable. A summary of the 
yields and characterisation data may be viewed in Table 2.9. 
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Table 2.9 Characterisation summary for heteroleptic complexes. 
  Yield HRMS HPLC  








Gradient Retention  
(min) 
Relative peak 
area 254 nm (%) 
UV / λmax (nm)  
(ε (M-1.cm-1)), H2O 
1 Pt(1,10-phenanthroline)(3,4,7,8-tetramethyl-
1,10-phenanthroline)]Cl2 
32.4% 34.8% 305.5824 305.5818 10-50 10.4 94.9 226 (62,900 ± 700) 
276 (41,800 ± 400) 
2 [Pt(1,10-phenanthroline)(4,7-dimethyl-1,10-
phenanthroline)]Cl2 
- 29.7%* 291.5668 291.5671 10-50 9.4 95.3 - 
3 [Pt(4,7-diphenyl-1,10-phenanthroline)(1,10-
phenanthroline)]Cl2 
28.5% 17.1% 353.5824 353.5826 10-50 14.6 98.1 225 (65,600 ± 800) 
283 (42,600 ± 400) 
303 (43,700 ± 500) 
4 [Pt(4,7-diphenyl-1,10-phenanthroline)(3,4,78-
tetramethyl-1,10-phenanthroline)]Cl2 
30.7% 31.1% 381.6137 381.6132 0-100 11.0 96.6 223 (60,700 ± 700) 
284 (41,100 ± 600) 
300 (42,000 ± 600) 
5 [Pt(4,7-diphenyl-1,10-phenanthroline)(4,7-
dimethyl-1,10-phenanthroline)]Cl2 
30.7% 22.9% 367.5981 367.5983 0-100 10.4 94.7 227 (55,900 ± 300) 
281 (40,400 ± 400) 
303 (40,900 ± 300) 
6 [Pt(4,7-diphenyl-1,10-phenanthroline)(5,6-
dimethyl-1,10-phenanthroline)]Cl2 
28.3% 16.5% 367.5981 367.5981 0-100 10.4 92.9 228 (58,500 ± 900) 
293 (43,700 ± 600) 
7 [Pt(4,7-diphenyl-1,10-phenanthroline)(5-chloro-
1,10-phenanthroline)]Cl2 
7.1% 12.8% 370.5630 371.0633 10-50 14.7 95.7 228 (67,900 ± 900) 
288 (47,800 ± 600) 
300 (46,700 ± 500) 
8 [Pt(4,7-diphenyl-1,10-phenanthroline)(2,2′-
bipyridine)]Cl2 
20.4% 11.7% 341.5824 341.5816 10-50 13.6 96.1 - 
9 [Pt(4,7-diphenyl-1,10-phenanthroline)(4,4′-
dimethyl-2,2′-bipyridine)]Cl2 
22.0% 17.2% 355.5981 355.5982 10-50 15.1 92.7 - 
10 [Pt(4,7-diphenyl-1,10-phenanthroline)(5,5′-
dimethyl-2,2′-bipyridine)]Cl2 
21.0% 13.8% 355.5981 355.5980 10-50 15.2 96.1 - 
11 [Pt(4,7-diphenyl-1,10-phenanthroline)(1S,2S-(+)-
1,2-Diaminocyclohexane)]Cl2 
62.6% - 320.6059 320.6052 10-50 12.0 95.6 228 (33300 ± 200) 
291 (40600 ± 200) 
12 [Pt(4,7-diphenyl-1,10-phenanthroline)(1R,2R-
(−)-1,2-Diaminocyclohexane)]Cl2 
61.7% - 320.6059 320.6052 10-50 12.1 96.0 228 (33300 ± 100) 
291 (40000 ± 100) 
*Reaction between [Pt(1,10-phenanthroline)2]Cl2 and Pt(4,7-dimethyl-10-phenanthroline)2]Cl2 
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2.6.8. Complex stability and confirmation of ligand coordination via 1H-195Pt 
NMR 
Obtaining a platinum shift was an ongoing challenge when characterising the 
synthesised complexes. Due to low water solubility of complexes 3-12, 1H NMR 
acquisition was first attempted in DMSO-d6. Initial proton spectra indicated that 
complex 3 and complexes 7–10 immediately began to break down in DMSO-d6. 
Complexes 5 and 6 were also found to break down but at a much slower rate. 
Surprisingly, HPLC analysis of a sample of complex 3 indicated that the homoleptic 
complexes had begun to form. This was possibly due to a DMSO solvolysis interaction 
although no similar cases have been reported for similar bis-phenanthroline 
complexes. Therefore, it is hypothesised that one of the ligands is displaced by DMSO 
to form a semi-stable intermediate. The coordinated DMSO may then be displaced by 
a free ligand in solution to form either the heteroleptic or homoleptic complexes. Over 
time, this would result in the same distribution of species present in the crude 
reactions. 
Thus, to determine if a DMSO interaction was responsible for this ligand exchange 
process, each complex was dissolved in D2O and monitored over several days to 
determine stability. From this study, complexes 3, and 7–10 were found to undergo 
this same ligand exchange process in D2O over several weeks to form the homoleptic 
complexes, indicating a similar mechanism. This degradation was easiest to visualise 
when tracking complex 7, which was observed to break down over the course of 3 
days as indicated by the broadening of peaks and overall downfield peak shift (Figure 
2.29). Of all the complexes tested, complexes 4, 5 and 6 were stable in D2O, while 
complexes 1, 2, 11 and 12 were stable in both D2O and DMSO-d6. Of the complexes 
stable in both DMSO and D2O, all but 2 were successfully purified.  
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Figure 2.29 Degradation of complex 7 over three days. 1H spectra in D2O at 298 K. 
With stability in mind, samples prepared for any long experiments, such as 1H-195Pt or 
NOSEY acquisition, were prepared immediately prior to analysis. Due to the relatively 
high molar masses and poor solubility of the complexes, samples were typically 
prepared to a 0.5-2 mM concentration range in D2O. To obtain a platinum shift, several 
parameters needed to be adjusted, including a high receiver gain, FID of 128 in the 
F1 dimension compared to the previously configured 256, and a short relaxation delay. 
From here, the number of scans was set between 200 to 300 depending on sample 
concentration, thus a typical experiment was conducted overnight, spanning between 







An interesting observation was noted when attempting to gather a spectra of complex 
5 in DMSO-d6 (Figure 2.30). As this complex appeared to break down relatively slowly, 
a 1H-195Pt NMR experiment was performed. Over the course of the experiment, only a 
small amount of the homoleptic complexes would be expected to form, thus a platinum 
shift for the heteroleptic complex should still be obtained. Surprisingly, a platinum shift 
was obtained for one of the breakdown products. Due to the presence of multiple 
components, it could not be determined which homoleptic complex this platinum shift 
correlated to. 
Figure 2.30 1H-195Pt spectra of complex 5 in DMSO-d6 at 298 K. 1H spectra overlaid in F2 






2.6.9. Investigating ligand lability - an alternate synthesis 
Previous investigation of the formation of heteroleptic complexes established that 
phen ligands could be quite labile. Interestingly, the outcomes of all the tested 
reactions were quite similar; the distribution of products appeared to follow a 
consistent trend. It appeared that under typical reaction conditions, bis-phen type 
complexes would reach a state of equilibrium between the homoleptic and heteroleptic 
complexes, based upon which complex is most stable (Figure 2.31). 
Figure 2.31 Proposed equilibrium between labile 1,10-phenanthroline ligands. 
To test this theory, the reaction between equimolar ratios of [Pt(1,10-
phenanthroline)2]Cl2 and [Pt(4,7-dimethyl-1,10-phenanthroline)2]Cl2 was investigated. 
Three separate 15 minute reactions at 100, 120 and 150 oC were conducted. For the 
100 oC reaction, the HPLC trace indicated minor formation of a new peak at 
7.3 minutes. When the reaction temperature was increased to 120 oC, the intensity of 
this peak increased significantly, resulting in a peak distribution similar to a traditional 
synthesis. Interestingly, for the 150 oC reaction, the same peak distribution was 
observed, however the peaks were quite broad, similar that observed with the one pot 
synthesis of [Pt(1,10-phenanthroline)(3,4,7,8-tetramethyl-1,10-phenanthroline)]Cl2. 
To confirm the identity of the heteroleptic complex, flash chromatography was used to 
isolate the unknown peak. Based on the relatively low HPLC retention of the 
components, a 0–25% methanol gradient was used. Some peak tailing was observed, 
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however, HPLC indicated relatively good separation. Interestingly, whilst 1H NMR of 
the second peak indicated that [Pt(1,10-phenanthroline)(4,7-dimethyl-1,10-
phenathroline)]Cl2 had formed, there were several impurities present. Despite this, 1H-
195Pt and ESI-MS data supported that the complex had been formed.  
In an attempt to obtain a cleaner product, an additional reaction was conducted. To 
avoid any complications that may arrive from the aforementioned method, a traditional 
microwave synthesis was performed by reacting [Pt(1,10-phenanthroline)Cl2] with 4,7-
dimethyl-1,10-phenanthroline. This resulted in similar product formation observed by 
HPLC. However, despite using several gradients and flow rates, adequate purification 
of this complex was not achieved.  
2.6.10. Increasing complex stability whilst maintaining QDNA stabilising 
properties  
From the prior synthesised complexes, it was evident that ligand lability was a major 
issue when designing bis-N,N’ type complexes. Subsequent review of the literature 
pointed towards the use of a diamminocyclohexane ancillary ligand as a means of 
increasing both complex solubility and stability.70 Presently, several [Pt(PL)(DACH)]2+ 
analogues have been synthesised, however no such syntheses incorporating 4,7-
diphenyl-1,10-phenanthroline have been reported. Thus, if 4,7-diphenyl-1,10-
phenanthroline ligand could be incorporated, the large planar aromatic surface could 
allow for quadruplex stabilising interactions to be increased substantially relative to 
currently reported literature analogues. 
Synthesis was initially attempted under reflux conditions using [Pt(DACH)Cl2] and 4,7-
diphenyl-1,10-phenanthroline based upon the reported literature method for 
analogous complexes.70 Unsurprisingly, this process was unsuccessful due to the 
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poor solubility of the 4,7-diphenyl-1,10-phenanthroline ligand. To overcome this 
limitation, microwave synthesis was investigated based upon prior successes. The 
synthesis was investigated using both R,R- and S,S-DACH enantiomers. Upon cooling 
of both reactions, a small amount of fine brown precipitate formed which was filtered 
to allow for the preparation of HPLC samples. Unlike the previously synthesised 
heteroleptic complexes, there was only one major product that had formed with 
minimal impurities. 
1H NMR analysis of the crude samples indicated that the desired complexes had 
formed, however there were some minor impurities present in the aliphatic region. 
Separation of these impurities was attempted using a Biotage SNAP Ultra C18 (30 g) 
column, however there was limited improvement. Despite this, both ESI-MS and HPLC 
indicated a high degree of purity (>95%). Yields were around ~60% for both 
complexes, boasting a substantial improvement over the bis-phen complexes. 
Subsequent investigation into stability indicated a ten-fold increase in solubility relative 
to the bis-N,N’ complexes synthesised in addition to complete stability when left 










3. In silico Molecular 
Docking Simulations  
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3.1. Technical specifications – Hardware and Software  
Simulations were performed using a AMD Ryzen 5 2600X 3.6 GHz processor, with 8 
GB of DDR4 RAM running Windows 10 64-Bit Edition. To prepare substrates and 
complexes, ChemDraw Ultra 12.0, Avogadro 1.20, UCSF Chimera 1.13.1 and 
MGLTools 1.5.6 were used. Docking simulations were performed using AutoDock Vina 
1.1.2. Data was processed using OriginPro 8.5. UCSF Chimera 1.13.1 was used to 
view docking poses and generate images.  
3.2. Methodology 
3.2.1. Preparation of metal complexes 
Structures for the investigated platinum complexes were first generated in Chemdraw 
then imported into Avogadro. Optimal complex geometry was determined using the 
UFF force field algorithm. Next, the structure was exported as a .PDB file to allow 
processing with AutoDockTools. For the complexes incorporating 4,7-diphenyl-1,10-
phenanthroline, rotatable bonds were specified for the phenyl functional groups. The 
processed complexes were then exported as .PDBQT files to allow for compatibility 
with AutoDock Vina.  
3.2.2. Preparation of DNA substrates 
DNA substrates were sourced from their respective protein data bank entries. Any 
non-standard residues, including water molecules, ions, or ligands, were removed 
using UCSF Chimera. The modified substrate was then imported into AutoDock tools 
to add polar hydrogens added. To define binding regions, the dimensions of the 
substrate were determined using the grid box tool. Grid coordinates for each substrate 
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are reported in Appendix Figure F.1. Lastly, the substrate was exported as a .PDBQT 
file to allow for compatibility with AutoDock Vina. 
3.2.3. Docking methodology 
Configuration files were generated for each DNA substrate based on the determined 
grid coordinates. As the search space for several of the DNA motifs exceeded 27,000 
angstroms, a high exhaustiveness value of 48 was used, based on literature 
recommendations.94 This was necessary as each docking simulation consists of 
several independent runs, specified by an exhaustiveness value. For each run, a 
random conformation is assigned based on a randomly generated seed. In the context 
of large substrates, a higher exhaustiveness value increases the probability that the 
assigned conformations coincide with the most favourable energy states.  
3.3. Selection of DNA substrates 
Five DNA substrates were chosen for this study based on their PDB structures. Two 
of which were conventional double stranded DNA motifs. The remaining three were 
quadruplexes with distinct structures. An overview of the properties of each substrate 
and their identifying PDB IDs are detailed below.  
PDB ID: 1BNA — The crystal structure of a conventional B-DNA dodecamer formed 
from the synthetic 12mer, sequence: [d(CGCGAATTCGCG)2] (Figure 3.1).95 This PDB 
model was chosen as an archetypal right-handed dsDNA helix. 1BNA is commonly used 
in docking simulations, providing a robust model for the analysis of groove binding 
interactions. 
PDB ID: 1CX3 — The solution structure of a bis-intercalated dsDNA hexamer, 
sequence: [d(ATGCAT)2] and the bis-naphthalimide drug LU-79553.96 Once 
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processed to remove the intercalating molecule, subsequent docking simulations 
allow for potential intercalation interactions to be observed with ICX3 (Figure 3.1). 
Figure 3.1 PDB models of dsDNA substrates. Images rendered with UCSF Chimera. 
PDB ID: 1XAV — The solution structure of a 22mer unimolecular G-quadruplex, 
sequence: [d(TG(AGGGTGGGT)2AA)] (Figure 3.2).97 This model is intramolecular 
parallel quadruplex, isolated from the promoter region of the human c-MYC oncogene. 
This region has been implicated in control of transcription of the c-MYC oncogene, the 
upregulation of which is linked to the incidence of several cancers,98 thus 1XAV 
represents a relevant QDNA target. Due to its high stability, this quadruplex motif was 
chosen for later ESI-MS binding experiments. 
PDB ID: 1LVS — The solution structure of a 11mer bimolecular G-quadruplex with a 
novel fold, sequence [d(GGGGTTTTGGG)2] (Figure 3.2).99 This model was chosen 
due to its unique hybrid conformation; two 11mer sequences fold to form an 
asymmetric dimeric fold back structure. As 1LVS is well characterised, it was later 
used for CD melting studies. 
PDB ID: 1KF1 — The crystal structure of a 22mer human telomere quadruplex, 
sequence [d(AGGG(TTAGGG)3)] (Figure 3.2).100 This oligomer is considered to be an 
1BNA    1CX3 
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archetypal telomere sequence. This sequence has been observed to form a 
quadruplex structure at an intracellular K+ concentration, stabilised by several central 
K+ ions. This substrate exhibits an approximate four-fold symmetry across three 
guanine-tetrads.  
Figure 3.2 PDB models of QDNA substrates. Images rendered with UCSF Chimera. 
3.4. Results and Discussion 
Each MC-substrate docking combination was repeated five times, outputting the nine 
most favourable binding poses; the most optimal binding geometries based on 
minimum binding energies (kcal.mol-1) and root square mean deviation (RSMD) 
values. The data for each replicate was then collated and the binding affinities for each 
pose averaged. The averaged data was then plotted as box plots, allowing for outliers 
to be determined. Overall average binding affinities with outliers removed can be 
viewed in Table 3.1. 
3.4.1. 1BNA 
Typical groove binding interactions were observed between all complexes and 1BNA. 
The generated boxplot for 1BNA can be seen in Figure 3.3. Complex 6 was observed 
to have the highest binding affinity, with an average binding affinity of −9.9 kcal.mol-1. 
An example binding pose for complex 6 may be seen in Figure 3.4. Complexes 5 and 
1XAV       1LVS    1KF1 
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7 had similar binding affinities to 6, with both complexes exhibiting an average binding 
affinity of −9.7 kcal.mol-1.  
Table 3.1 Average predicted binding affinities for complexes 1–12. Complexes with the 
highest average binding affinity (kcal.mol-1) for each substrate are highlighted in green. 
Complex 1BNA 1CX3 1XAV 1LVS 1KF1 
1 −8.3 −6.6 −8.1 −7.3 −9.6 
2 −8.9 −6.9 −8.1 −7.4 −9.2 
3 −9.5 −8.0 −8.3 −7.7 −10.0 
4 −8.7 −8.3 −8.6 −7.1 −10.4 
5 −9.7 −8.4 −8.2 −7.6 −10.3 
6 −9.9 −8.1 −8.5 −8.1 −10.3 
7 −9.7 −8.0 −8.2 −7.9 −10.1 
8 −9.0 −7.6 −8.0 −7.4 −9.3 
9 −9.2 −8.0 −8.0 −7.5 −9.5 
10 −8.8 −7.1 −7.9 −7.0 −9.7 
11 −8.2 −7.7 −7.6 −7.2 −8.4 
12 −8.5 −7.7 −8.1 −7.4 −8.8 
This observation indicated that small functional groups such as methyl or chlorine 
groups in the 4,5,6 and 7 positions of the 1,10-phenanthroline ligand enhanced 
selectivity for duplex DNA. Interestingly, complex 4 displayed the lowest binding 
affinity of the bis-phenanthroline complexes incorporating 4,7-diphenyl-
phenanthroline. This suggested that substituents in the 3 and 8 positions inhibit groove 
binding interactions, as these substituents widen rather than extend the planar surface 
of the complex. Complexes 1, 11 and 12 had the lowest average binding affinities with 
values of −8.3, −8.2 and −8.5 kcal.mol-1, respectively. Given that the bis-phen 
complexes incorporating 4,7-diphenyl-phenanthroline exhibited higher overall binding 
affinities, this suggested that binding affinity correlated strongly with aromaticity.  
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Figure 3.3 Boxplot of average binding poses for complexes 1–12 when docked with 1BNA. 





For this substrate, intercalation of the investigated complexes appeared to be quite 
unfavourable. Complexes 4, 11 and 12 observed intercalation interactions for one out 
of the nine binding poses, however for complexes 11 and 12, these were found to be 
significant statistical outliers (Figure 3.5). In the case of complex 4, the 4,7-diphenyl-
1,10-phenanthroline was observed to partially insert between two base pairs as 
illustrated in Figure 3.6. For the remaining complexes, typical groove binding 
interactions were observed. For this DNA, complex 5 exhibited the highest binding 
affinity with an average of −8.4 kcal.mol-1. Complex 4 exhibited the second-best 
binding affinity with an average of −8.3 kcal.mol-1. This observation was interesting 
considering that complex 4 exhibited relatively low binding affinity towards 1BNA. This 
difference was thus attributed to the ability of 4 to intercalate with the double stranded 
1CX3. Complexes 1, 2, 11 and 12 exhibited the lowest binding affinities with values of 
−6.6, −6.9, −7.7 and −7.7 kcal.mol-1, respectively; again, reinforcing the correlation 
between aromaticity and binding affinity. 
Figure 3.5 Boxplot of average binding poses for complexes 1–12 when docked with 1CX3. 
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Figure 3.6 Most favourable binding pose of complex 4 when docked with 1CX3. 
3.4.3. 1XAV 
For this substrate, both groove binding and end-stacking interactions were observed. 
For each complex, end-stacking was observed to be the most favourable binding pose, 
however several complexes exhibited both binding modes. Complexes 1-3 were 
observed to bind only via end-stacking, whereas the remaining complexes displayed 
a mix between the two binding modes. An example of each of the two types of binding 
poses is displayed in Figure 3.7. Relative to the other DNA motifs tested, the data was 
spread over a much larger range, resulting in several outliers (Figure 3.8). In most 
cases this was observed to occur when the binding mode changed between end-
stacking and groove-binding for the first and second poses, respectively. From the 
data, complex 4 exhibited the highest binding affinity, with an average binding value 
of −8.6 kcal.mol-1. This complex was found to be the only complex incorporating 4,7-
diphenyl-1,10-phenanthroline which bound predominantly via end-stacking 
interactions. This was hypothesised to be as a result of the increased substitution of 
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the 3,4,7,8-tetramethyl-1,10-phenanthroline ligand, with the presence of four methyl 
groups significantly increasing end-stacking interactions. Complex 6 was a close 
second, with an average binding affinity of −8.5 kcal.mol-1, however this complex 
observed a mix of end-stacking and groove-binding interactions. Complex 11 exhibited 
the lowest binding affinity, with a value of −7.6 kcal.mol-1.  
Figure 3.7 Example docking poses of complex 6 when docked with 1XAV. 
Figure 3.8 Boxplot of average binding poses for complexes 1–12 when docked with 1XAV.  




For this substrate, all complexes exhibited groove binding interactions as seen in 
Figure 3.9. Whilst the data was spread over a larger range than the other substrates, 
only four statistical outliers were observed (Figure 3.10). Interestingly, the overall 
distribution was quite similar to 1BNA, with complex 6 again having the highest binding 
affinity (−8.1 kcal.mol-1). Again, complex 4 had significantly lower binding affinity 
(−7.1 kcal.mol-1), further reinforcing that substituents in the 3 and 8 positions reduce 
groove binding affinity.  
Figure 3.9 Example docking poses of complex 6 when docked with 1LVS. 






For this substrate, all complexes exhibited end-stacking interactions as seen in Figure 
3.11. Relative to the other substrates, the data was more tightly distributed, with only 
one minor statistical outlier observed for complex 7 (Figure 3.12). Complex 4 exhibited 
the highest binding affinity (−10.4 kcal.mol-1), which was unsurprising as this complex 
has the largest planar surface. The DACH enantiomers 11 and 12 exhibited the lowest 
binding affinities overall, with averages of −8.4 and −8.8 kcal.mol-1, which correlated 
with their relatively small aromatic surface.  
Figure 3.11 Example docking pose of complex 4 when docked with 1KF1. 
Figure 3.12 Boxplot of average binding poses for complexes 1–12 when docked with 1KF1. 
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3.5. Overall complex rankings 
From the collated data it was clear that the degree of aromaticity gave a strong positive 
correlation with binding affinity. Some selectivity was observed for the telomeric 
quadruplex 1KF1, evident through the lower overall binding affinities, however all 
complexes also showed notable affinity for 1BNA. Intercalation with dsDNA was found 
to be unfavourable, although complex 4 did appear to intercalate under one of the 
docking poses. When contrasting the results observed for both dsDNA and QDNA, it 
was found that the functional groups of the ligand had a minimal effect on selectivity 
between dsDNA and QDNA. Instead, it was revealed that the specific position of 
functional groups would either enhance or diminish specific interactions. Functional 
groups in the 4, 5 ,6 and 7 positions extended out of the ends of the complex, thus 
increasing both groove binding and end-stacking interactions. Methylation of 3 and 8 
positions, as seen in the case of complex 4, widening the surface area of the complex, 
decreasing groove binding affinity whilst increasing end-stacking interactions. 
Summaries of the rankings for each complex for dsDNA and QDNA substrates are 
reported in Table 3.2 and Table 3.3, respectively. 
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Table 3.2 Predicted binding affinities for the synthesised complexes in dsDNA substrates, ranked by predicted binding energy. Highest and 
lowest ranked complexes in each substrate are highlighted in green and red, respectively. 
1BNA  1CX3 
Rank Complex Mean binding affinity 
(kcal.mol-1) 
 Rank Complex Mean binding affinity 
(kcal.mol-1) 
1 6 -9.9  1 5 -8.4 
=2 5 -9.7  2 4 -8.3 
=2 7 -9.7  3 6 -8.1 
3 3 -9.5  =4 7 -8.0 
4 9 -9.2  =4 3 -8.0 
5 8 -9.0  =4 9 -8.0 
6 2 -8.9  =5 12 -7.7 
7 10 -8.8  =5 11 -7.7 
8 4 -8.7  6 8 -7.6 
9 12 -8.5  7 10 -7.1 
10 1 -8.3  8 2 -6.9 





Table 3.3 Predicted binding affinities for the synthesised complexes in QDNA substrates, ranked by predicted binding energy. Highest and 
lowest ranked complexes in each substrate are highlighted in green and red, respectively. 
 
1XAV  1LVS  1KF1 
Rank Complex 
Mean binding affinity 
(kcal.mol-1) 
 Rank Complex 
Mean binding affinity 
(kcal.mol-1) 
 Rank Complex 
Mean binding affinity 
(kcal.mol-1) 
1 4 -8.6  1 6 -8.1  1 4 -10.4 
2 6 -8.5  2 7 -7.9  2 5 -10.3 
3 3 -8.3  3 3 -7.7  2 6 -10.3 
=4 7 -8.2  4 5 -7.6  3 7 -10.1 
=4 5 -8.2  5 9 -7.5  4 3 -10.0 
=5 1 -8.1  6 2 -7.4  5 10 -9.7 
=5 2 -8.1  6 12 -7.4  6 1 -9.6 
=5 12 -8.1  6 8 -7.4  7 9 -9.5 
=6 8 -8.0  7 1 -7.3  8 8 -9.3 
=6 9 -8.0  8 11 -7.2  9 2 -9.2 
7 10 -7.9  9 4 -7.1  10 12 -8.8 











4. In vitro Studies 
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4.1. Circular Dichroism Melting Studies 
4.1.1. Materials 
The lypholised oligomers 5’-TGA GGG TGG GTA GGG TGG GTA A-3’ (Q1) and 5’-
GGG GTT TTG GGG-3’ (Q2) were purchased from LGC Biosearch Technologies, 
Denmark and were used as received without further purification. Potassium fluoride 
and potassium phosphate were obtained from Sigma-Aldrich. Complexes 1, 3–7 and 
11–12 were used for this study. 
4.1.2. Instrumentation 
Spectra were obtained using a Jasco J-810 CD polarimeter. To control temperature 
during melting studies a Jasco peltier temperature regulator was used. All experiments 
used a sealed quartz cuvette with a path length of 1 mm, with sample volumes of 
250 µL. CD spectra measurements were performed at 20 ºC between 350–200 nm 
with the following parameters: 1 second response time, 100 nm.min-1 scan rate and 
20 accumulations. Melting experiments were performed over a 20–100 °C 
temperature range. Data was collected at 1 ºC intervals over a 1 ºC.min-1 ramp rate 
and response time of 4 seconds. All samples were allowed to equilibrate for 15 
minutes prior to measurements.  
4.1.3. Preparation of QDNA 
The lypholised oligomers were dissolved in potassium phosphate buffer comprised of 
KH2PO4/K2PO4 (25 mM, pH 7.3) and potassium fluoride (75 mM). Each oligomer was 
dissolved in buffer solution to achieve a target concentration of 0.2 mM based on the 
yields provided by the supplier. Concentration was determined spectrophotometrically 
using the following extinction coefficients ε260 = 227,800 M-1cm-1 (Q1) and ε260 = 
105,100 M-1cm-1 (Q2), as provided by the suppliers. Following determination of 
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concentration, the olilgomers Q1 and Q2 were annealed by heating at 95 ºC for 15 
minutes, then they were allowed to cool to room temperature to form the QDNA motifs 
1XAV and 1LVS.  
4.1.4. DNA thermal stabilisation 
Stability of duplex DNA is strongly dependent on both hydrogen bonding interactions 
between complementary based pairs and base-stacking interactions.101, 102 This also 
holds true for quadruplex DNA; both Höögsten hydrogen bonding and base-stacking 
interactions strongly influence stability.46 When heated, these hydrogen bonding 
interactions are disrupted, causing the DNA to denature. This process causes a loss 
in secondary structure and thus a loss in chirality, which may be observed by CD. By 
plotting the CD intensity over a given temperature range, a melting curve can be 
generated. The inflection point of this curve denotes the TM value for the observed 
DNA motif, the temperature where 50% of the DNA is denatured.103  
4.1.5. QDNA Melting point determination 
To determine ideal melting wavelengths, CD spectra between 200–350 nm for 1XAV 
and 1LVS were obtained (Figure 4.1). For a wavelength to be considered ideal, an 
adequate signal to noise ratio is required. Both oligomers observed local maximums 
of adequate intensity at ~205 nm, however, these were disregarded due to lower 
signal to noise ratios. Negative maximums were observed around ~240 nm for both 
oligomers, however their lower ellipticity prohibited Tm analysis. Consequently, the 
remaining peaks at 265 nm for 1XAV, and 262 and 287 nm for 1LVS, were determined 
to be suitable candidates for analysis. 
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Figure 4.1 Circular dichroism spectra of 1XAV (blue) and 1LVS (red). 
Melting experiments were performed over a temperature range of 20–100 ºC with a 
ramp rate of 1 ºC.min-1 with a 40 µM sample concentration. The collected data was 
then processed using OriginPro 8.5. To determine melting point, the data was first 
normalised and then 7-point Savitzky-Golay smoothing applied. Next, a standard 
Boltzman function was fitted (Equation 1),  
𝐶𝐷 = 𝐶𝐷𝑚𝑖𝑛 +  
(𝐶𝐷𝑚𝑎𝑥 − 𝐶𝐷𝑚𝑖𝑛)




where TM is the point of inflection and CDmax and CDmin are the points of maximum 
and minimum CD intensity, respectively. Values for TM were obtained from this 
inflection point of the curve (Figure 4.2). Under the tested buffer conditions, 1XAV 
exhibited a TM of 75.7 ºC at 265 nm. For 1LVS, the peak at 262 nm exhibited a slightly 
lower TM of 62.7 ºC and for the peak at 287 nm, a substantially lower TM of 47.6 ºC 
was noted. The 287 nm peak for 1LVS was determined to be ideal for DNA-MC melting 



























These important characteristics ensure an adequate temperature range from which 
stabilisation effects may be observed. 
QDNA Peak wavelength (nm) TM (ºC) 
1XAV 265 75.7 ± 0.3 
1LVS 
262 62.7 ± 0.4 
287 47.6 ± 0.2 
Figure 4.2 Normalised sigmoidal fits of melting curves for 1XAV and 1LVS. 
4.1.6. MC-QDNA melting experiments 
To determine the stabilising effect of the synthesised complexes, melting experiments 
used an equimolar ratio of MC:QDNA. As each of the tested complexes contain large 
planar aromatic ligands, it would be expected that MC-QDNA stacking interactions 
would result in an increase in TM. Metal complexes were prepared to a 1 mM stock 
concentration in phosphate buffer solution (25 mM KH2PO4/K2PO4 and 75 mM KF). 
Samples containing MC and QDNA were then prepared to a final concentration of 40 
µM. Prior to analysis, samples were vortexed and equilibrated for 15 minutes. To verify 


















1XAV 265 nm 1LVS 287 nm 1LVS 262 nm
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obtained. Melting experiments were then performed using the same parameters as 
prior experiments without MC. Normalised melting curves of 1LVS with each tested 
metal complex are illustrated in Figure 4.3. 
Figure 4.3 Normalised melt profile at 287 nm of 1LVS + MC with 21-point Savitzky-Golay 
smoothing applied. 
4.1.7. Results and discussion 
Following preliminary analysis of the data using OriginPro 8.5, it was clear that only 
the melting curves for complexes 11 and 12 conformed to a sigmoidal trend. For the 
other complexes used in the study, the melting profile appeared to be biphasic. This 
was most evident for complex 1, where there appeared to be a potential transition 
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Figure 4.4 Normalised and smoothed melt profile of 1LVS + complex 1. 
At room temperature, 1LVS is a hybrid structure comprised of two d(G4T4G3) 
oligonucleotides. These g-rich strands are reported to form an asymmetric dimeric fold 
back structure.99 The hybrid nature of this oligomer is significant, as similar hybrid 
structures have been observed to undergo conformational changes in the presence of 
quadruplex-targeting ligands.104 This posed the hypothesis that at different 
temperatures there is an induced preference for either a parallel or antiparallel 
configuration due to the addition of bis-phen type metal complexes.  
To investigate this hypothesis, a new sample of 1LVS with complex 1 was prepared 
and CD spectra at several temperature ranges recorded (Figure 4.5). CD spectra 
obtained after addition of the metal complex showed a reduction of the peak at 262 nm 
and slight increase in the peak at 287 nm, confirming that a conformational change 
had occurred. According to literature work, antiparallel quadruplexes typically display 
a positive peak around 290 nm and a negative peak around 260 nm,105 therefore, this 
change suggested an increased preference towards an antiparallel configuration. At 
70 ºC this peak ratio was reversed, with the higher peak intensity of the 262 nm peak 





















Subsequent spectra at 75 ºC displayed a return to an even peak ratio, similar to the 
quadruplex melt without a metal complex. This accounts for the increase in CD 
intensity observed between 70 to 80 ºC for the prior melting experiments. At 80 ºC, 
the 287 nm peak was similar in intensity to the 75 ºC spectra, however the peak at 
262 nm was no longer clearly observable, indicating that the quadruplex was almost 
fully denatured. See Figure 4.6 for a summary of the proposed mechanism. 
Figure 4.5 CD spectra of 1LVS + Complex 1 at various temperature ranges. 
 

















1LVS 1LVS + Complex 1 20 ⁰C 1LVS + Complex 1 70 ⁰C
1LVS +Complex 1  75 ⁰C 1LVS +Complex 1  80 ⁰C
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As the melting curves for complexes 11 and 12 followed a sigmoidal trend, the 
processed data was fitted using a standard Boltzmann equation (Figure 4.7). TM 
values of 55.2 ± 0.5 ºC for complex 11 and 56.2 ± 0.5 ºC for complex 12 were 
determined from the points of inflection. As both enantiomers had a very similar 
stabilising effect, it was evident that the DACH ligand did not play an important role in 
the stabilisation process. As this curve was purely sigmoidal, this suggests that the 
large planar and aromatic surface of the bis-phen complexes was responsible for the  
conformational change discussed earlier.  
Figure 4.7 Processed melting curves for 1LVS + complexes 11 and 12. 
Due to the non-sigmoidal nature of the remaining complexes, a different approach was 
required to determine TM values for the remaining melt curves. Attempts were made 
to fit the data in Origin Pro 8.5 using the available biphasic functions, however these 
functions failed to fit the acquired data. Thus, to allow analysis, first and second 
derivatives of the raw melting curves were taken to determine points of inflection. As 
the initial data was quite noisy, 7-point Savitzky-Golay smoothing was applied to the 
first derivative, and 15-point smoothing to the second. For a given data point to be 
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concavity needed to occur. Due to the nature of the data, several inflection points were 
observed for each complex, thus specific criteria were set for identifying inflections. 
Keeping in mind that the CD signal decreased in intensity as temperature increased, 
only points with a negative first derivative, and changes in concavity from concave 
down to concave up, were considered. As complexes 3–7 appeared to have a similar 
transition state to 1, two points of inflection were chosen. The first of which was the 
point of melting of the initial state of DNA (TM-A), and the other the midpoint of the 
melting of the transition state (TM-B). For segments of a curve with multiple inflection 
points, the point was taken that best aligned with the middle of the segment based on 
the fraction folded value. An example of this process can be seen in Figure 4.8 and 
Figure 4.9, respectively. Four inflection points were identified at 40.5, 49.3, 67.6 and 
88.1 ºC. The inflection point at 49.3 ºC best correlated to the midpoint of the initial 
curve segment, thus this was assigned to TM-A. The point at 67.8 ºC appeared to 
correlate with the formation of the transition state thus this peak was disregarded. The 
remaining peak at 88.0 ºC correlated with the melting of the transition state to its 
apparent point of denaturation. 
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Figure 4.9 First derivative of melting curve of 1LVS + complex 1. 
Complexes 3-7 were processed in the same way as complex 1. Values for TM-A and 
TM-B are reported in Table 4.1. Unsurprisingly, TM-A values proved to be of limited 
usefulness due to the non-sigmoidal curve shape. From this analysis, complex 3 and 
6 exhibited the highest TM-A values. When consulting the normalised data, complex 3 
appeared to have the second lowest stabilisation amongst the tested bis-phen 
complexes. The TM-B values were somewhat more useful, providing the following 
ranking for stabilisation of the transition state: 6 > 5 > 1 > 3 > 7 > 4. When compared 
to the raw data, this ranking held true for all complexes except 4, which appeared to 
have a stabilisation ability in-between 1 and 3. Relative to complex 11 and 12, the bis-
phen complexes appeared to have a greater stabilisation effect, however the presence 
of a transition state induced by these complexes prevented an accurate comparison 
from being deduced. 
Table 4.1 Values for TM-A and TM-B determined via derivative analysis. 
Ranking Complex TM-A (ºC) TM-B (ºC) 
1 6 51.0 ± 1.1 92.5 ± 0.5 
2 5 47.9 ± 0.3 91.1 ± 1.1 
3 1 49.3 ± 0.1 88.1 ± 0.7 
4 4 50.0 ± 0.3 86.0 ± 1.0 
5 3 51.0 ± 0.1 87.6 ± 0.6 
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4.2. ESI-MS Binding studies 
4.2.1. Materials 
The lypholised oligomer 5’-TGA GGG TGG GTA GGG TGG GTA A-3’ (Q1) was 
purchased from LGC Biosearch Technologies, Denmark. The oligomer was further 
purified using a Porapak Rxn CX 20 cc cation exchange column obtained from Waters. 
Ammonium acetate was purchased from Sigma-Aldrich. Previously synthesised 
complexes 1, 3–7 and 11–12 were used for this study. 
4.2.2. Purification of the supplied oligomer 
The oligomer 5’-TGA GGG TGG GTA GGG TGG GTA A-3’ was purified using a 
Waters Porapak Rxn CX 20 cc column. A flow rate of 1 mL.min-1 was maintained using 
a Bio-Rad low pressure peristaltic pump. The column was first equilibrated by eluting 
methanol (10 mL), water (10 mL) and then ammonium acetate buffer solution (100 mL, 
150 mM, pH 7.0). The lypholised oligomer was dissolved in ammonium acetate buffer 
solution (250 μL, 150 mM, pH 7.0) and then eluted with ammonium acetate. A Bio-
Rad UV detector was used to detect the purified oligomer as it eluted.  The purified 
oligomer (8 mL) was collected then lyophilised. Once dried, the oligomer was then 
reconstituted in ammonium acetate buffer and the concentration determined 
spectrophotometrically then diluted to a final concentration of 200 μM. This was 
achieved using the extinction coefficient ε260 = 228,700, as provided by the supplier. 
The oligomer was then annealed by heating in a water bath at 95 °C for 5 min, after 
which is was then allowed to cool to room temperature over several hours. 
4.2.3. Preparation of ESI-MS samples 
1 mM stock solutions of complexes 1, 3–7 and 11–12 were prepared in ammonium 
acetate buffer (150 mM, pH 7.0). Samples were prepared as per Table 4.2 to achieve 
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a final QDNA concentration of 20 μM with one, three or five equivalents of metal 
complex. 
Table 4.2 Volumes of 1XAV and and MC for ESI-MS sample preparation. 
 Volume (μL) 
1XAV:MC ratio 1:1 1:3 1:5 
1XAV  3.0 3.0 3.0 
MC  0.6 1.8 3.0 
Buffer 26.4 25.2 24.0 
Total 30.0 30.0 30.0 
4.2.4. Instrumentation 
Samples were analysed using a Waters XEVO SYNAPT G2-S QTOF ESI mass 
spectrometer with a Z-spray ionisation source. Spectra were obtained using a cone 
voltage of 50 V, capillary tip potential of 2.2 kV, and microchannel plate (MCP) 
potential of 2.2 kV. The source temperature was configured to 70 oC. Desolvation gas 
flow was set to 150 L.hr-1 at 150 oC. Samples were injected with a Harvard Apparatus 
Pump 11 Elite syringe pump at an infusion rate of 5 μL.min-1. All spectra were obtained 
in negative ion mode over a 500–3000 m/z range. MassLynx v4.2 was used for data 
processing. For each sample, a 5 min window of data was combined across a m/z 
range of 700 to 3000, as to encompass all visible QDNA charge states, then the data 
smoothed using the mean smoothing method with 2 smooths applied.  
4.2.5. Methodology 
Electrospray ionisation mass spectrometry (ESI-MS) is a common technique used for 
the characterisation of non-covalent interactions between ligands and biological 
targets such as DNA, RNA or proteins.106, 107 ESI-MS is an incredibly useful technique 
as it allows for the evaluation of binding affinity and stoichiometry of non-covalent 
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complexes. Relative to other techniques, preparation of samples is a simple, rapid 
process, allowing for analysis of aqueous mixtures, even at very low concentrations, 
without the need for isotopic labelling.108, 109 This is important to consider, as such 
modifications are often costly and may significantly alter binding interactions.107  
Experimental parameters for the study of binding interactions between duplex DNA 
and various small molecules have already been well developed in the literature.110, 111 
Several recent studies have focused on adapting these conditions for the analysis of 
non-conventional DNA structures such as triplexes or quadruplexes.112-115 Despite the 
relatively high stability of several QDNA motifs compared to duplex DNA, soft source 
conditions must be utilised to maintain sample integrity. A careful balance must be 
struck when configuring instrument parameters. Cone voltage is one of the most 
important parameters as it not only effects degree of ionisation but also sample 
integrity. If the voltage is too high, QDNA-salt adducts become more prevalent and 
fragmentation of the QDNA may occur.116 However, if the voltage is too low, ionisation 
will be reduced and the sensitivity too low. Desolvation temperature is another 
important consideration, as if the temperature is too high, secondary structure of the 
DNA will be lost. Typically, a temperature range of 60–75 °C is sufficient in maintaining 
a reasonable ion count whilst still maintaining DNA integrity.116 Choice of buffer is also 
important in order to maintain DNA conformation. Traditionally used phosphate or 
Tris/HCl buffers are not compatible with ESI-MS conditions as they are non-volatile.117 
Instead, a volatile buffer such as ammonium acetate must be used; forming volatile 
ammonia or acetic acid ions under ESI-MS conditions.  
High sample purity is crucial to obtaining interpretable results. Prior to analysis, the 
oligomer must first be purified to remove excess salt ions such as K+ or Na+. This is a 
crucial step as these ions will form adducts with the DNA. Given that the abundance 
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of the DNA and DNA-ligand complexes is already low, such adducts will result in a 
significant loss in sensitivity.  
For this study, the quadruplex motif 1XAV was due to its relatively high melting 
temperature of ~ 85 °C.97 Prior to analysis, the supplied oligomer was purified using a 
Waters Porapak Rxn CX 20 cc cation-exchange column to remove any salt-ion 
contaminants then lyophilised. Following lypholisation, the oligomer was then 
dissolved in ammonium acetate buffer and annealed by heating to 95 oC for 5 minutes, 
then allowing it to slowly cool to room temperature. To determine concentration and 
verify DNA structure, UV-Vis and circular dichroism experiments were performed and 
stock solutions prepared. Prior to preparation of the ESI-MS samples, the solubilities 
of the synthesised metal complexes were tested. Complexes 1, 3–7 and 11–12 were 
chosen for this study due to their stability in aqueous solution and adequate solubility. 
A summary of this process can be seen in Figure 4.10. 
Figure 4.10 Summary of sample preparation for ESI-MS binding studies.  
4.2.6. Results and discussion 
ESI-MS of the purified oligomer indicated three abundant peaks at m/z values of 
1169.9, 1404.1 and 1755.3, respectively (Figure 4.11). Taking into account the 
expected mass for 1XAV of 6991.6 Da, the following species assignments were made. 
The 6− state was assigned to the peak at the m/z value of 1169.9, correlating to [1XAV 
+ 2NH4⁺ – 8H⁺]6⁻.  Next, the 5− state was assigned to the peak at the m/z value of 
1404.1 m/z, correlating to [1XAV + 2NH4⁺ – 7H⁺]5⁻. Finally, the 4− state was assigned 
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to the m/z value of 1755.3 m/z, correlating to [1XAV + 2NH4⁺ – 6H⁺]4⁻. As NH4+ ions 
do not  readily form adducts with the DNA, the presence of NH4+ ions suggested that 
the quadruplex structure was retained in the gas phase, with the NH4+ ions bound 
within the central cavity.116 Whilst the 5− charge state was found to be the most 
abundant state both before and after addition of the metal complex, all charge states 
were considered when determining the ratio of bound metal complex. Approximate 
ratios of bound and unbound complex were determined based on the combined ion 
counts for each given peak.  
Figure 4.11 Negative ion ESI-Ms spectrum of 1XAV. 
Of the tested complexes, 1 appeared to have the greatest binding affinity for 1XAV. 
For the 1:1 sample, both the 5− and 4− charge states were observed, however the 5− 
state was the prevalent form irrespective of complex binding (Figure 4.12). Based on 
the total ion counts, 17% of the DNA was observed to be unbound, 55% bound to one 
equivalent of metal complex, and 28% bound to two equivalents. For both the 3:1 and 
5:1 sample, the DNA was almost completely bound with two equivalents of complex. 
Relative to the other complexes tested, 1 was the only complex which was observed 
to completely bind at a 3:1 metal complex to DNA ratio.  
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Figure 4.12 Negative Ion ESI MS of 1XAV + various equivalents of complex 1. 
For the 1:1 sample, complex 3 demonstrated limited binding to 1XAV, with an 
estimated 68% of DNA in the unbound state, and the remaining 32% bound with one 
equivalent of complex (Figure 4.13). For the 3:1 sample, there was very little free 1XAV 
left (~3%). Approximately 37% of the DNA was bound to one equivalent of metal 
complex, and the remaining 60% to two equivalents. For the 5:1 sample, >99% of the 
DNA was bound to two equivalents of complex. 
Figure 4.13 Negative Ion ESI MS of 1XAV + various equivalents of complex 3.  
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Complex 4 demonstrated a moderate binding affinity towards 1XAV (Figure 4.14). For the 1:1 
sample, approximately 27% of the DNA was unbound, 58% bound to one equivalent of 
complex, and the remaining 15% bound to two equivalents. For the 3:1 sample, approximately 
7% of the DNA was unbound, 56% bound to one equivalent and the remaining 37% bound to 
two equivalents of complex. For the 5:1 sample, >99% of the DNA was bound to two 
equivalents. 
Figure 4.14 Negative Ion ESI MS of 1XAV + various equivalents of complex 4. 
Complex 5 proved to be an outlier relative to the other samples tested. For the 1:1 
sample, the DNA appeared to be almost completely bound (Figure 4.15). However, 
there were several unknown peaks at around m/z values of 2217 and 2320 which 
could not be attributed to any combination of DNA and metal complex, even when 
accounting for the potential loss of NH4⁺ ions; this suggested some form of 
degradation. To ensure that this was not due to an error in sample preparation, a new 
metal complex stock was prepared. From this stock a new sample was made, however 
a similar result was observed. For the 1:1 sample, it appeared that approximately 40% 
of the DNA was bound to one equivalent and 35% to two equivalents. The remaining 
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DNA was bound to some form of degradation product, which was hypothesised to be 
a mixture of free ligand and [Pt(PL)Cl2]. For the 3:1 sample, approximately 8% of the 
DNA was bound to one equivalent and 90% to two equivalents. Again, a degradation 
product was observed at a m/z of 2320. Surprisingly, the 5:1 sample observed the 
DNA to be fully bound with two equivalents of complex, with no other major peaks 
present. 
Figure 4.15 Negative Ion ESI MS of 1XAV + various equivalents of complex 5. 
The acquired spectra for complex 6 displayed similar degradation peaks to 5, however 
the overall distribution was much more consistent with the prior samples (Figure 4.16). 
For the 1:1 sample, approximately 25% of the DNA was unbound, 55% bound to one 
equivalent, and 16% to two equivalents. For the 3:1 sample, 15% of the DNA was 
bound with one equivalent of complex and 82% to two. For the 5:1 spectrum, >99% of 





Figure 4.16 Negative Ion ESI MS of 1XAV + various equivalents of complex 6. 
Despite the limited stability of complex 7, the acquired spectra were surprisingly clean 
(Figure 4.17). For the 1:1 sample, approximately 30% of the DNA was unbound, 60% 
bound to one equivalent of complex, and the remaining 10% bound to two equivalents. 
For the 3:1 sample, 85% of the DNA was bound to two equivalents and the remaining 
15% to one equivalent. Near complete binding of the DNA with two complex molecules 
was observed for the 5:1 sample. 
Figure 4.17 Negative Ion ESI MS of 1XAV + various equivalents of complex 7. 
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The spectra for complexes 11 and 12 presented an interesting contrast to the prior 
samples. For the bis-phen complexes, a maximum of two complex molecules were 
observed to bind to 1XAV molecule. However, in the case of complexes 11 and 12, a 
maximum of three complex molecules were observed to bind. This is hypothesised to 
be due to the smaller surface area of the overall complex due to the coordination of 
the DACH enantiomers, thus the binding of a third complex is more sterically 
favourable. This was supported by docking simulations, from which complex 1 was 
observed to bind to two regions of the DNA, whereas complex 11 was observed to 
bind to three regions of the DNA (Figure 4.18).  
Figure 4.18 1XAV docked with complex 1 (left) and complex 11 (right). Image rendered with 
UCSF Chimera. 
 For complex 11, the initial 1:1 spectra observed approximately 21% of the DNA to be 
unbound, 71% bound with one equivalent of complex, and 8% with two equivalents 
(Figure 4.19). For the 3:1 sample, 6% of the DNA was unbound, 46% bound to one 
equivalent, 34% to two equivalents and the remaining 14% to three. Surprisingly for 
the 5:1 sample, there was still unbound DNA (~7%). 44% of the DNA was bound with 
one equivalent, 33% with two equivalents, and 16% with three equivalents. As only 




Figure 4.19 Negative Ion ESI MS of 1XAV + various equivalents of complex 11. 
Relative to complex 11, 12 exhibited similar binding interactions between 1XAV 
(Figure 4.20) and up to three complex molecules, however the apparent binding affinity 
was lower. As complex 11 and 12 incorporated the enantiomers S,S-DACH and R,R-
DACH, this observation demonstrated that chirality has a modest influence on binding 
affinity. For the 1:1 sample, approximately 66% of the DNA was unbound, a substantial 
reduction from the 21% unbound observed for complex 11. The remaining 34% was 
bound to one equivalent of complex, with no discernible two-equivalent binding. For 
the 3:1 sample, 10% of the DNA was observed in the unbound state, 63% bound to 
one equivalent of complex, and the remaining 27% to two equivalents. The binding of 
three equivalents of complex was only observed for the 5:1 sample, where 5% of the 
DNA was unbound, 47% bound to one equivalent of complex, 35% bound to two 
equivalents and 13% to three equivalents. Overall, the binding affinity of 12 was lower 
than observed for 11 for each of the 1, 3 and 5 equivalent samples. This indicated that 
the chirality of the DACH ligand plays an important role in binding interactions, with 
the SSDACH enantiomer best maximising DNA-complex interactions. 
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Figure 4.20 Negative Ion ESI MS of 1XAV + various equivalents of complex 12. 
Overall, all of the investigated bis-phen complexes exhibited a strong binding affinity 
for 1XAV. For the 5:1 samples, 1XAV was observed to fully bind with two equivalents 
of each complex, with complexes 11 and 12 being the only exceptions. To allow 
relative binding affinities to be ranked, analysis focused upon the 3:1 samples. 
Complex 1 exhibited the highest binding affinity with >99% of the DNA bound with two 
equivalents of complex. Complex 5 appeared to have the second highest binding 
affinity of 90% bound to two equivalents, even when considering the presence of 
several degradation peaks; further investigation is required to determine their exact 
nature. Complexes 6 and 7 had almost identical binding affinity. Complex 7 had a 
slightly higher binding affinity with 85% bound to two equivalents and thus it was 
ranked third. The slightly lower affinity of complex 6 (82% bound to two equivalents) 
was attributed to the presence of several degradation peaks, thus this complex was 
ranked fourth. Complex 3 had a lower binding affinity, with 60% bound to two 
equivalents, being ranked sixth overall. This provided an interesting comparison to 
complex 7, from which the 1,10-phenanthroline ligand was substituted with 5-chloro-
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1,10-phenanthroline. This difference in binding affinity of 7 suggested that the chlorine 
group substantially enhanced electrostatic interactions between the complex and 
DNA. Despite being the most soluble of the bis-phenanthroline complexes, 4 exhibited 
a significantly lower binding affinity, with 37% of the DNA bound to two equivalents of 
metal complex. The DACH enantiomers had the lowest binding affinity, with complex 
11 being ranked 7th and complex 12 being ranked 8th, with 34% and 27% of the DNA 
bound to two equivalents of complex, respectively. A summary of the approximate 
percentages of complexes bound at a 3:1 MC:1XAV ratio can be seen in Table 4.3. 





1 eq. MC bound 
(%) 
2 eq. MC bound 
(%) 
3 eq. MC bound 
(%) 
1 1 0 0 >99% N/A 
2 5 0 8 90 N/A 
3 7 0 15 85 N/A 
4 6 0 15 82 N/A 
5 3 3 37 60 N/A 
6 4 7 56 37 N/A 
7 11 6 46 34 14 





4.3. Cell line testing 
4.3.1. Methodology 
Complexes 1, 3-7 and 11-12 were used for this study based on their suitable solubility 
profiles. Cytotoxicity assays were performed at the Calvary Mater Newcastle Hospital, 
Waratah, NSW, Australia. Tested cell lines included colon carcinoma (HT29), 
glioblastoma (U87), breast cancer (MCF-7), ovarian cancer (A2780), lung cancer 
(H460), skin cancer (A431), prostate cancer (Du145), neuroblastoma (BE2-C), 
glioblastoma (SJ-G2), pancreas cancer (MIA), and the non-tumour derived breast cell 
line (MCF10A). All complexes were prepared as 25 mM stock solutions in DMSO and 
stored at −20 °C. Cell lines were cultured in a humidified 5% CO2 atmosphere at 37 °C 
and maintained in Dulbecco's modified Eagle's medium supplemented with 10% foetal 
bovine serum, 10 mM sodium bicarbonate penicillin (100 IU.mL−1), streptomycin 
(100 μg.mL−1), and glutamine (4 mM). The non-cancer cell line, MCF10A was cultured 
in DMEM: F12 (1 : 1) cell culture media, 5% heat inactivated horse serum, 
supplemented with penicillin (50 IU.mL−1), streptomycin (50 μg.mL−1), 20 mM Hepes, 
l-glutamine (2 mM), epidermal growth factor (20 ng.mL−1), hydrocortisone 
(500 ng.mL−1), cholera toxin (100 ng.mL−1), and insulin (10 μg.mL−1). Cytotoxicity was 
determined by plating cells in duplicate in 100 mL medium at a density of 2500–4000 
cells per well in 96 well plates. On day 0, (24 h after plating) when the cells were in 
logarithmic growth, 100 μL medium with or without the tested complex was added to 
each well. After 72 hours, drug exposure growth inhibitory effects were evaluated 
using the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide) assay 
and absorbance read at 540 nm. An eight-point dose response curve was produced 
from which the GI50 value was calculated, representing the drug concentration at which 
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cell growth was inhibited by 50% based on the difference between the optical density 
values on day 0 and those at the end of drug exposure. 
4.3.2. Results and discussion 
GI50 values for the tested complexes are reported in Table 4.4. All complexes exhibited 
higher average growth inhibition in cancer cell lines relative to carboplatin. When 
compared to cisplatin, all complexes except 5, 11 and 12 exhibited average GI50 
values more potent than cisplatin in the tested cancer cell lines. Relative to oxaliplatin, 
only complex 6 displayed a higher average potency. A summary of average GI50 
values and fold potency can be seen in Table 4.5. Relative to cisplatin, all complexes 
exhibited higher growth inhibition in colon (HT29) and pancreas (MIA) cancer cell lines. 
Excluding the ovarian (A2780) cancer cell line, complex 6 was found to be the most 
potent complex and 12 the least potent, with average GI50 values of 1 and 7.5 µM, 
respectively. In the colon (HT29) cell line, complex 6 exhibited a substantial ten-fold 
improvement (GI50 = 1.1 ± 0.5) over cisplatin (GI50 = 11.3 ± 1.19). Similar improvement 
was observed for the breast (MCF-7) and pancreas (MIA) cancer cell lines, with eight 
and seven-fold increases over cisplatin, respectively. In the remaining cell lines, 
complex 6 exhibited an almost four-fold increase over cisplatin in the glioblastoma 
(U87) cell line, and a two-fold increase in both the skin (A431) and neuroblastoma 
(BE2-C) cancer cell lines. In the prostate (Du145) cancer cell line, complex 6 (GI50 = 
1.1 ± 0.7) had similar growth inhibition to cisplatin (GI50 = 1.2 ± 0.1), however the error 
was quite large and thus this needs to be taken into consideration. In the ovarian 
(A2780) cancer cell line, complex 6 exhibited identical potency to cisplatin (GI50 = 1.0), 
and thus was ranked second. For this cell line, complex 1 had slightly higher growth 
inhibition (GI50 = 0.86 ± 0.67). No complexes showed improved activity over cisplatin 
in lung (H460) or glioblastoma (SJ-G2) cell lines. 
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When comparing the tested complexes to oxaliplatin, only complex 6 showed an 
overall higher cytotoxicity than oxaliplatin, with an average fold potency of 1.7. The 
most notable increase in activity was observed for the skin (A431) cancer cell line, 
from which complex 6 exhibited a four-fold increase (GI50 = 1.1 ± 0.84) over Oxaliplatin 
(GI50 = 4.1 ± 0.5). In the remaining cell lines, close to a two-fold increase was observed 
for the glioblastoma (U87) and prostate (DU145) cancer cell lines and only marginal 
improvement for the H460 and BE2-C cell lines. 
Minimal selectivity was observed for cancerous breast cells over healthy cells. Instead, 
the cytotoxicity observed in the MFC10A normal breast cell line correlated with the 
average GI50 values observed for cancerous cell lines. The only notable exception was 
complex 1 in the A2780 cell line. Whilst this complex only observed a minimal increase 
in potency over complex 6, a three-fold decrease in activity in the MFC10A cell line 
was observed. It must be noted that the error values were quite large for this cell line, 
thus further investigation would be required to verify this apparent selectivity. 
Overall, complex 6 was determined to have the highest potency against cancer cell 
lines (Figure 4.21). When considering the structure of the tested complexes, the bis-
phenanthroline complexes exhibited higher activity than the DACH enantiomers 11 
and 12, indicating a larger aromatic surface correlates with increased activity. The 
position of functional groups was also shown to have a notable effect on activity. 
Complexes 6 and 7 exhibited the highest activity, both of which incorporated differing 
functional groups in the 5 and 6 positions. This has been previously observed with 
methyl substitution of the complex [Pt(1,10-phenanthroline)(1S,2S-
diaminocyclohexane)]2+ (mean GI50 = 0.47 µM) and [Pt(5,6-dimethyl-1,10-
phenanthroline)(1S,2S-diaminocyclohexane)]2+ (mean GI50 = 0.052 µM).70 The only 
exception to this trend was observed for A2780 cell line, where 1 exhibited higher 
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activity, potentially indicating that the phenyl rings reduce activity. Complex 5 proved 
to be a significant outlier to the other tested complexes, with significantly lower potency 
relative to analogous compounds. As this complex was observed to break down in 
ESI-MS, this suggests the poor stability of the complex results in reduced activity.  The 
overall stability of the tested bis-phen complexes in DMSO was reflected by the 
observed error values, with significant errors observed for the Lung (H460) cell line. 
 
Figure 4.21 GI50 values of Complex 3 Complex 6, and Complex 7 in (HT29), 
glioblastoma (U87 and SJ-G2), ovarian (A2780), lung (H460), skin (A431), prostate (Du145), 
neuroblastoma (BE2-C), pancreas (MIA), breast (MCF-7), and breast normal (MCF10A) cell 





































































































Table 4.4 Anticancer activity of a selected range of platinum(II) complexes, GI50 (µM) recorded against 11 cell lines. 
 
HT29 U87 MCF-7 A2780 H460 A431 Du145 BE2-C SJ-G2 MIA MCF10A 
Complex Colon Glioblastoma Breast Ovarian Lung Skin Prostate Neuroblastoma Glioblastoma Pancreas Breast 
(Normal) 
1 2.9 ± 0.32 2.6 ± 0.27 6.3 ± 1.5 0.86 ± 0.67 2.4 ± 0.34 2.6 ± 0.20 2.5 ± 0.29 2.1 ± 0.81 2.5 ± 0.32 2.7 ± 0.23 3.1 ± 0.13 
3 3.0 ± 0.033 2.6 ± 0.15 2.0 ± 0.23 1.0 ± 0.73 2.7 ± 0.56 2.6 ± 0.35 2.2 ± 0.29 1.6 ± 0.71 2.2 ± 0.33 2.3 ± 0.28 3.1 ± 0.15 
4 3.1 ± 0.40 2.4 ± 0.27 3.4 ± 0.21 1.3 ± 0.72 2.3 ± 0.32 2.7 ± 0.19 2.7 ± 0.17 1.6 ± 0.44 2.4 ± 0.43 2.4 ± 0.12 3.0 ± 0.17 
5 12 ± 9.6 7.8 ± 5.6 12 ± 9.0 6.0 ± 4.0 9.7 ± 7.2 10 ± 7.5 8.9 ± 6.6 5.5 ± 3.8 10 ± 8.3 7.2 ± 4.9 8.6 ± 5.7 
6 1.1 ± 0.75 1.0 ± 0.67 0.88 ± 0.51 1.0 ± 0.91 1.2 ± 0.86 1.1 ± 0.84 1.1 ± 0.77 0.79 ± 0.65 0.82 ± 0.59 1.0 ± 0.83 1.1 ± 0.82 
7 2.2 ± 0.39 1.2 ± 0.62 3.1 ± 0.55 1.0 ± 0.83 2.5 ± 0.15 1.8 ± 0.58 1.8 ± 0.63 1.4 ± 0.74 1.9 ± 0.088 1.5 ± 0.54 2.9 ± 0.088 
11 7.7 ± 0.98 1.2 ± 0.20 6.8 ± 0.33 2.0 ± 0.86 4.7 ± 0.41 3.4 ± 1.4 4.1 ± 2.0 18 ± 5.0 2.8 ± 0.36 2.1 ± 0.12 4.8 ± 0.17 
12 11 ± 0.33 2.9 ± 0.30 9.4 ± 2.0 2.3 ± 0.99 5.8 ± 0.68 4.8 ± 0.63 8.0 ± 5.0 25 ± 3.7 3.4 ± 0.62 2.7 ± 0.10 11 ± 0.33 
Cisplatin 11.3 ± 1.9 3.8 ± 1.1 6.5 ± 0.8 1.0 ± 0.1 0.9 ± 0.2 2.4 ± 0.3 1.2 ± 0.1 1.9 ± 0.2 0.4 ± 0.1 7.5 ± 1.3 nd 
Oxaliplatin 0.9 ± 0.2 1.8 ± 0.2 0.5 ± 0.1 0.16 ± 0.0 1.6 ± 0.1 4.1 ± 0.5 2.9 ± 0.4 0.9 ± 0.2 3.0 ± 1.2 0.9 ± 0.2 nd 





Table 4.5 Average of GI50 values (Concentration µM) and fold potency against cisplatin, 
oxaliplatin, and carboplatin. Yellow indicates no increase in fold potency. Most potent complex 
6 is highlighted in green. 
  
Fold potency increase  
Complex Average* GI50 values (µM) Cisplatin Oxaliplatin Carboplatin 
1 2.75 1.3 0.6 5.3 
3 2.22 1.7 0.8 6.5 




6 1.00 3.7 1.7 14.4 
7 1.84 2.0 
 
7.8 
11 5.28   2.7 
12 7.53   1.9 
Cisplatin 3.69 - - - 
Oxaliplatin 1.68 - - - 


















5.1. Synthesis of Platinum complexes  
A library of twelve complexes incorporating various 1,10-phenanthroline, bipyridine, 
1R,2R-diamminocyclohexane and 1S,2S-diamminocyclohexane ligands were 
synthesised. Emphasis was placed on complexes incorporating 4,7-diphenyl-1,10-
phenanthroline in order to increase potential quadruplex stabilising interactions. For 
the bis-N,N′- type complexes, the ligands were found to be surprisingly labile. During 
synthesis, there was no preference for the formation of the desired heteroleptic 
complexes, instead a mixture of homoleptic and heteroleptic complexes was 
observed. Even when isolating several of the heteroleptic complexes, the homoleptic 
complexes were found to reform through a ligand exchange mechanism. Future efforts 
aim to investigate this distribution of products, utilising both experimental data and 
computer-based simulations to determine how electron density effects complex 
stability. From preliminary investigation it appeared that the complexes with methyl 
substituents were relatively more stable, thus this would be an ideal starting for further 
research.  
Whilst the lability of the ligands was an issue, this also inspired the investigation of 
alternate syntheses. The first of which was a one-pot synthesis from which two ligands 
could be reacted directly with K2PtCl4 starting material. Whilst this proved to be an 
effective, time-efficient method for the synthesis of complex 1, it was less effective 
than conventional synthesis methodologies when using ligands such as the 2,2’-
bipyridine derivatives. Future development would benefit from investigating the use of 
this method with a broader range of ligands to determine its overall viability. The 
second method evaluated the direct reaction between two homoleptic complexes to 
form the desired heteroleptic complex. Whilst this method appears counter-intuitive, 
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conventional synthesis of heteroleptic bis-N,N′ complexes typically results in formation 
of the homoleptic complexes which are later isolated via chromatography. Rather than 
discarding these products, they may be accumulated over several runs, from which 
the synthesis of other complexes in this manner may be investigated.  
5.2. Optimising 1H-195Pt Experiments 
1H-195Pt experiments are an important means of confirming ligand coordination. Due 
to issues with stability and solubility for the investigated complexes, a low signal to 
noise ratio was a consistent issue, resulting in prolonged experiment times, often 
exceeding 10 hours. To facilitate further investigation of analogous complexes, the 
determination of more optimal parameters would be extremely valuable, allowing for 
timely analysis of unstable or poorly soluble samples.  
The most effective way to increase the signal-to-noise ratio would be to determine the 
relaxation time of the Pt nucleus, then adjust the experiment parameters accordingly. 
Typically, this may be achieved by adjusting the acquisition or relaxation delay times. 
If adjusting these parameters proves to be insufficient, adjusting sample temperature 
may be another potentially effective means of increasing signal. Typically, relaxation 
time is temperature dependant. Presently, the relaxation times of analogous platinum 
complexes with a bis-N,N′ coordination sphere have seen minimal investigation, thus 
further studies would prove beneficial. If more optimal parameters could be 
determined, the time required to confirm the coordination of the platinum to these 




5.3. Docking simulations 
Each of the twelve synthesised complexes were docked with two dsDNA motifs and 
three QDNA motifs. A clear trend was seen between increasing complex aromaticity 
and binding affinity. Whilst some selectivity was observed for the human telomeric 
quadruplex 1KF1, the complexes also exhibited strong binding affinity for 1BNA. For 
the remaining DNA motifs, no preference for either dsDNA of QDNA was observed. 
These results correlated quite closely with the ESI-MS and CD experiments, with a 
few notable exceptions. For the ESI-MS binding experiments, complex 1 exhibited the 
highest binding affinity, despite being ranked fifth in the docking experiments. This was 
hypothesised to be due to the higher solubility of this complex relative to other 
complexes investigated; a property which was not taken into consideration by the 
docking software. For the CD melting experiments, complex 7 was ranked last despite 
exhibiting the second highest binding affinity in the docking experiments. This was 
attributed to the relatively low stability of this complex in solution. 
5.4. Binding studies 
Both ESI-MS and CD melting experiments demonstrated the binding affinity of the 
complexes for QDNA and their stabilising effects. As only QDNA motifs were 
investigated, future work would benefit from repeating these experiments with 
synthetic dsDNA oligomers. This would provide data complementary to docking 





5.5. Overall complex rankings 
The binding affinity and activity for the fully investigated complexes 1, 3–7, and 11–12 
were ranked from highest to lowest as per Table 5.1. Rankings were based on the 
averaged rankings of all of the performed experiments, including the average QNDA 
docking affinity, ESI-MS, CD melt and GI50 rankings. Complex 6 was ranked highest 
overall, exhibiting both the strongest binding affinity for QDNA and greatest potency in 
cell lines. Complex 7 was ranked second, with a reasonable QDNA binding affinity and 
second highest cell line activity. The remaining bis-phenanthroline complexes 
exhibited reasonable binding affinities, however they exhibited lower cell line activity. 
Whilst both 11 and 12 were found to be the only complexes stable in DMSO, these 
complexes exhibited the lowest overall binding affinity and activity in cancer cell lines, 
thus these were ranked last. 
Table 5.1 Overall rankings of complex binding affinity and cell line activity. 
 Complex Docking ESI-MS CD Melts Average GI50 Overall 
6 
[Pt(4,7-diphenyl-1,10-phenanthroline)  
(5,6-dimethyl-1,10-phenanthroline)]Cl2 1 4 1 1 1 
7 
[Pt(4,7-diphenyl-1,10-phenanthroline) 
(5-chloro-1,10-phenanthroline)]Cl2 2 3 6 2 2 
1 
Pt(1,10-phenanthroline) 
(3,4,7,8-tetramethyl-1,10-phenanthroline)]Cl2 5 1 3 5 3 
5 
[Pt(4,7-diphenyl-1,10-phenanthroline) 
(4,7-dimethyl-1,10-phenanthroline)]Cl2 =3 2 2 8 4 
3 
[Pt(4,7-diphenyl-1,10-phenanthroline) 
(1,10-phenanthroline)]Cl2 =3 5 5 3 5 
4 
[Pt(4,7-diphenyl-1,10-phenanthroline) 
(3,4,78-tetramethyl-1,10-phenanthroline)]Cl2 4 6 4 4 6 
11 
[Pt(4,7-diphenyl-1,10-phenanthroline) 
(1S,2S-(+)-1,2-Diaminocyclohexane)]Cl2 7 7 7 6 7 
12 
[Pt(4,7-diphenyl-1,10-phenanthroline) 





5.6. Future synthetic directions 
The labile nature of the tested phen and bipy ligands is a major concern when 
attempting to develop a Pt(II) complex with acceptable in vivo stability. Given the vast 
range of phen and bipy ligands available, the investigation of a broader range of 
heteroleptic complexes would provide useful insights into stability. This investigation 
may also be extended to include cycloplatinated complexes, for the purpose of 
determining how ligands such as 2-phenyl-pyridine and benzo[h]quinolone affect both 
complex stability and solubility. Previous work has already established microwave-
assisted synthesis to be an effective means of producing cycloplatinated complexes,86 
thus the conditions established for the synthesis of complexes 1–12 may be adapted 
for the synthesis of various cycloplatinated bis-N,N′ derivatives (Figure 5.1). 
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6.1. Appendix A — NMR spectra 
 
Figure A.1. 1H spectra of [Pt(1,10-phenanthroline)2]Cl2 in D2O at 298 K. 
 











Figure A.3. 1H-195Pt spectra of [Pt(1,10-phenanthroline)2]Cl2 in D2O at 298 K. 
 
Figure A.4. 1H spectra of [Pt(4,7-dimethyl-1,10-phenanthroline)2]Cl2 in D2O at 298 K. 
 
H2 / 9.21 / -2246 ppm 








Figure A.5. COSY spectra of [Pt(4,7-dimethyl-1,10-phenanthroline)2]Cl2 in D2O at 
298 K. 
 
Figure A.6. 1H-195Pt spectra of [Pt(4,7-dimethyl-1,10-phenanthroline)2]Cl2 in D2O 
at 298 K. 
H2 
H3 




Figure A.7. 1H spectra of [Pt(5,6-dimethyl-1,10-phenanthroline)2]Cl2 in D2O at 298 K. 
 












Figure A.9. 1H-195Pt spectra of [Pt(5,6-dimethyl-1,10-phenanthroline)2]Cl2 in D2O at 
298 K. 
 









Figure A.11. 1H-195Pt spectra of [Pt(3,4,7,8-tetramethyl-1,10-phenanthroline)2]Cl2 in 
D2O at 298 K. 
  
 
Figure A.12. 1H spectra of [Pt(4,4′-dimethyl-2,2′-bipyridine)2]Cl2 in D2O at 298 K. 







Figure A.13. COSY spectra of [Pt(4,4′-dimethyl-2,2′-bipyridine)2]Cl2 in D2O at 298 K. 
 
Figure A.14. 1H-195Pt spectra of [Pt(4,4′-dimethyl-2,2′-bipyridine)2]Cl2 in D2O at 298 K. 
H2 
H3 






Figure A.15. 1H spectra of complex 1 in D2O at 298 K. 
 















Figure A.17. NOSEY spectra of complex 1 in D2O at 298 K. 
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Figure A.19. 1H spectra of complex 2 in D2O at 298 K. 
 
















Figure A.21. NOSEY spectra of complex 2 in D2O at 298 K. 
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Figure A.23. 1H spectra of complex 3 in D2O at 298 K. 
 
Figure A.24. COSY spectra of complex 3 in D2O at 298 K. 
H2 + H2’ 
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Figure A.25. 1H-195Pt spectra of complex 3 in D2O at 298 K. 
 
Figure A.26. 1H spectra of complex 4 in D2O at 298 K. 
 














Figure A.27. COSY spectra of complex 4 in D2O at 298 K. 
 











Figure A.29.1H-195Pt spectra of complex 4 in D2O at 298 K. 
 

















Figure A.31. COSY spectra of complex 5 in D2O at 298 K. 
 











Figure A.33. 1H-195Pt spectra of complex 5 in D2O at 298 K. 
 
Figure A.34. 1H spectra of complex 6 in D2O at 298 K. 
H2 / 9.27 / -2284 ppm 












Figure A.35. COSY spectra of complex 6 in D2O at 298 K. 
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Figure A.37. 1H spectra of complex 7 in D2O at 298 K. 
 
Figure A.38. COSY spectra of complex 7 in D2O at 298 K. 
H2’ 
H9’ 
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Figure A.39. COSY with overlaid 1H spectra of complex 7 in D2O at 298 K. 
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Figure A.41. 1H spectra of complex 8 in D2O at 298 K. 
 















Figure A.43. 195Pt spectra of complex 8 in D2O at 298 K. 
 












Figure A.45. COSY spectra of complex 9 in D2O at 298 K. 
 









Figure A.47. 1H spectra of complex 10 in D2O at 298 K. 
 














Figure A.49.1H spectra of aromatic region of complex 11 in D2O at 298 K.  
 












Figure A.51. COSY spectra of aliphatic region of complex 11 in D2O at 298 K.  
 
Figure A.52. 1H-195Pt spectra of complex 11 in D2O at 298 K. 









Figure A.53. 1H spectra of aromatic region of complex 12 in D2O at 298 K. 
 














Figure A.55. COSY spectra of aliphatic region of complex 12 in D2O at 298 K.  
 
Figure A.56. 1H-195Pt spectra of complex 12 in D2O at 298 K.  








6.2. Appendix B — High Resolution ESI-MS 
 
Figure B.1. Complex 1: [Pt(1,10-phenanthroline)(3,4,7,8-tetramethyl-1,10-
phenanthroline)]Cl2. 
 
Figure B.2. Complex 2: [Pt(1,10-phenanthroline)(4,7-dimethyl-1,10-
phenanthroline)]Cl2. 
 





Figure B.4. Complex 4: [Pt(4,7-diphenyl-1,10-phenanthroline)(3,4,78-tetramethyl-
1,10-phenanthroline)]Cl2. 
 
Figure B.5. Complex 5: [Pt(4,7-diphenyl-1,10-phenanthroline)(4,7-dimethyl-1,10-
phenanthroline)]Cl2. 
 






Figure B.7. Complex 7: [Pt(4,7-diphenyl-1,10-phenanthroline)(5-chloro-1,10-
phenanthroline)]Cl2. 
 
Figure B.8. Complex 8: [Pt(4,7-diphenyl-1,10-phenanthroline)(2,2′-bipyridine)]Cl2. 
 






Figure B.10. Complex 10: [Pt(4,7-diphenyl-1,10-phenanthroline) (5,5′-dimethyl-2,2′-
bipyridine)]Cl2. 
 




Figure B.12. Complex 12: [Pt(4,7-diphenyl-1,10-phenanthroline)(1R,2R-(−)-1,2-
Diaminocyclohexane)]Cl2. 
   
164 
 
6.3. Appendix C — HPLC 
 
Figure C.1. HPLC trace of [Pt(1,10-phenanthroline)2]Cl2.10−50% eluent B over 15 
minutes. Top: 254 nm, Bottom: 214 nm. 
 
Figure C.2. HPLC trace of [Pt(4,7-dimethyl-1,10-phenanthroline)2]Cl2. 10−50% eluent 





Figure C.3. HPLC trace of [Pt(5,6-dimethyl-1,10-phenanthroline)2]Cl2. 10−50% eluent 
B over 15 minutes. Top: 254 nm, Bottom: 214 nm. 
 
Figure C.4. HPLC trace of [Pt(3,4,7,8-tetramethyl-1,10-phenanthroline)2]Cl2. 10−50% 





Figure C.5. HPLC trace of [Pt(4,4′-dimethyl-2,2′-bipyridine)2]Cl2. 10−50% eluent B 
over 15 minutes. Top: 254 nm, Bottom: 214 nm. 
 
Figure C.6. HPLC trace of complex 1. 10−50% eluent B over 15 minutes. Top: 





Figure C.7. HPLC trace of complex 2. 10−50% eluent B over 15 minutes. Top: 
254 nm, Bottom: 214 nm. 
 
Figure C.8. HPLC trace of complex 3. 10−50% eluent B over 15 minutes. Top: 




Figure C.9.HPLC trace of complex 4. 0−100% eluent B over 15 minutes. Top: 214 nm, 
Bottom: 254 nm. 
Figure C.10. HPLC trace of complex 5. 0−100% eluent B over 15 minutes. Top: 





Figure C.11.HPLC trace of complex 6. 0−100% eluent B over 15 minutes. Top: 214 
nm, Bottom: 254 nm. 
 
Figure C.12. HPLC trace of complex 7. 10−50% eluent B over 15 minutes. Top: 





Figure C.13. HPLC trace of complex 8. 10−50% eluent B over 15 minutes. Top: 
254 nm, Bottom: 214 nm. 
 
Figure C.14. HPLC trace of complex 9. 10−50% eluent B over 15 minutes. Top: 




Figure C.15. HPLC trace of complex 10. 10−50% eluent B over 15 minutes. Top: 
254 nm, Bottom: 214 nm. 
 
Figure C.16. HPLC trace of complex 11. 10−50% eluent B over 15 minutes. Top: 




Figure C.17. HPLC trace of complex 12. 10-50% eluent B over 15 minutes. Top: 




6.4. Appendix D — UV-Vis Spectra 
 
Figure D.1. UV-Vis spectra of complex 1 in H2O. 
 
  














































































Figure D.3. UV-Vis spectra of complex 4 in H2O. 
 



















































































Figure D.5. UV-Vis spectra of complex 6 in H2O. 
  




















































































Figure D.7. UV-Vis spectra of complex 11 in H2O. 
 













































































6.5. Appendix E — Circular dichroism spectra 
 
Figure E.1. Raw melting curves for 1XAV at 265 nm and 1LVS at 262 and 287 nm 
with sigmoidal fits. 
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Figure E.3. Normalised melting data for 1LVS with each tested complex at 287 nm. 
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Figure E.5. Circular dichroism spectra of 1LVS + MC at 20OC following melt 
experiment. 
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6.6. Appendix F — Docking grid coordinates 
Table F.1. Grid coordinates for processed substrates. 
Parameter Center x Center y Center z Size x Size y Size z 
1BNA 15 22 10 25 28 44 
1CX3 1 1.5 0 28 25 24 
1XAV 0 1 0 35 26 31 
1LVS 1 0.5 -1.5 24 30 26 
1KF1 25.3 -1.1 -9.2 35 31 43 
 
 
